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ABSTRACT 
       Eric Scott: Immune Cells and Type I Interferon in Systemic Lupus Erythematosus 
Patient Urine and Kidney Immunopathology 
(Under the direction of Stephen Clarke) 
Murine models have demonstrated that systemic lupus erythematosus (SLE) 
results in kidney damage due to antibody mediated tissue destruction. Studies of 
peripheral blood immune subsets in patients revealed the importance of T and B 
lymphocyte subsets that drive pathological antibody production. The 
immunopathological events in the kidneys of human SLE nephritis (LN) are poorly 
understood, in part due to a paucity of serial patient samples related to the risk of tissue 
biopsy procedures. To circumvent this, we investigated readily available patient urine 
that might contain immune mediators that correlate with kidney pathology and function. 
Flow cytometry analysis was performed on peripheral blood and urine cells of 28 non-
LN patients and 41 LN patients. The urine immune cell phenotypes were correlated with 
the class of LN and kidney function.  Sixty percent of non-LN patients had urine 
lymphocytes. Non-LN urine B cells were naïve and memory cell subsets and T cells 
were predominantly CD8+. In contrast, nearly all LN patients had urine lymphocytes. In 
half of LN patients, the B and T cells resembled those in non-LN patient urine; however, 
in the remaining patients, the B cells were exclusively plasmablasts or plasma cells 
(PB/PCs) and the T cells were predominantly CD4+. In addition, the urine contained 
plasmacytoid dendritic cells (pDCs) and IFNα/β. Patients with significantly increased 
 iv
PB/PCs were more likely to have proliferative nephritis, exhibit a significant loss of 
kidney function, and progress to end stage renal disease (ESRD).  We find that urine 
provides insight into the kidney immunopathology and may serve as biomarkers to 
identify patients at risk for developing LN and progressing to ESRD. 
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Chapter 1: Background and Introduction 
 
I. Brief overview of B cells and antibodies within the immune system 
 A functional human immune system provides protection from foreign pathogens. 
Innate and adaptive immune responses provide early detection and immunological 
memory, respectively. The innate immune system affords effective ‘first-line’ defense 
against invading organisms.   Pathogens that breach epithelial surfaces are immediately 
recognized, ingested, and killed by cells of the innate immune system.  This ‘first-line 
defense’ of the immune system detects unchanging components common to pathogens, 
but rarely found in the host. While immediately effective, the more primitive innate 
system lacks the ability to refine its actions against a specific pathogen or generate 
memory. In contrast, the adaptive immune system comprises T and B-lymphocytes that 
have evolved a more comprehensive and diverse means of defense increasing 
protection against infection and re-infections. 
 Antibody (Ab) produced by B cells is one important component of the adaptive 
immune system that operates in conjunction with the innate response and confers 
immunological memory. Abs can enhance the phagocytosis of pathogens via a process 
called opsonization, or by activating complement in Ab-antigen or so-called immune 
complexes (IC). Likewise, many complement components of the innate immune system 
are necessary for an efficient adaptive response against certain antigens (Frank MM. 
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1991, Tomlinson S. 1993). Binding of toll like receptor (TLRs) via their ligands can also 
control and direct the adaptive immune response (Heine H. 2003).  
Both the human and animal immune systems have evolved controls to respond to 
invading pathogens while protecting from damage of self.   
The immune system must discern self from non-self to provide immunity yet 
prevent autoimmunity. When this balance is imperfect, an immune response against 
self-tissue antigens and nuclear proteins may result in autoimmune diseases.  
Autoimmune responses are incited by specific self-antigens that are expressed on 
normal host tissues, leading to immune-mediated tissue and organ damage.  
Autoimmune diseases may be organ-specific and have aberrant immune Ab responses 
directed against antigen(s) associated only within target organs. Alternatively, 
autoimmunity can be classified as systemic (or non-organ specific) and have Ab 
directed against an antigen not associated with any particular target organ. Type I 
diabetes mellitus is an example of organ-specific autoimmunity where CD4+ T cells and 
CD8+ T cells destroy pancreatic beta cells in genetically predisposed individuals (Van 
Belle TL. 2011).  Systemic Lupus Erythematosus (SLE) is an example of systemic 
autoimmunity that is characterized by the production of autoantibodies (autoAbs) to 
cells within the body leading to widespread inflammation and tissue damage (Janeway 
CA. 2005).   
  This dissertation will focus on the study of peripheral B cell subsets in SLE to 
understand the molecular mechanisms that result in the loss of B cell tolerance to self-
antigens. The first part of this introductory chapter will focus on B cell development and 
distinct (‘immune tolerance’) mechanisms that help prevent autoimmunity.  The second 
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part of the chapter will review why B cells are considered central players in SLE, both as 
producers of pathological Abs and mediators in the autoimmune response.  
II. B cell development 
 B cell development begins in the bone marrow (BM) and continues in peripheral 
lymphoid organs.  B cells are regulated by signals from non-hematopoietic BM cells and 
other factors. Tissue resident BM stromal cells interact with developing B cells, 
providing signals through secreted growth factors and contact with cell-surface 
molecules (Srivastava B. 2005, Pieper K. 2013). B cells only exit the BM if they express 
functional cell surface immunoglobulin (sIg) called B Cell Receptor (BCR). The antigen 
specificity of each individual B cell is determined through the assembly of Variable (V), 
Diversity (D), and Joining (J) gene segments that comprise the BCR.  Pro-B cells 
upregulate the B cell lineage surface marker CD45R (B220 in mouse) and activate the 
recombination activating gene 1/2 (RAG1 and 2), to begin DJ rearrangement of their Ig 
heavy (H) chain under the control of the transcription factors E2A, EBF, and PAX-5 
(Srivastava B. 2005, Pieper K. 2013).  Pre-B cells up-regulate CD19, a BCR co-
receptor, and proceed with V-DJ rearrangement (Oettinger MA. 1990, Kim  DR. 2000, 
Collins  AM. 2003, Pieper K. 2013).  Upon H chain rearrangement, a surrogate Ig Light 
(L) chain is expressed to form the pre-BCR.  This marks the beginning of the pre-B cell 
stage (Oettinger MA. 1990, Kim  DR. 2000, Collins  AM. 2003, Pieper K. 2013).    
The pre-B cell stage is important in B cell development in that it determines if 
combinatorial and junctional diversification results in a functional H chain (Oettinger MA. 
1990, Kim  DR. 2000, Collins  AM. 2003, Pieper K. 2013).  If the rearranged H chain is 
non-functional, a second attempt is made to rearrange with an alternative H chain allele 
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(Collins  AM. 2003, Pieper K. 2013).  If the second rearrangement is unsuccessful, the 
cell undergoes apoptosis and dies.  If successful, the pre-B cell undergoes clonal 
expansion and proceeds to rearrange its L chain gene (Collins  AM. 2003, Pieper K. 
2013).  After rearrangement of both the H and L chains and both chains are expressed 
on the B cell surface, the cell is considered an immature B cell (Collins  AM. 2003, 
Pieper K. 2013).  Maturing B cells only survive if BCR-antigen engagement during 
development results in their being ‘selected.’ This central tolerance mechanism during B 
cell development is important to prevent the development of autoimmunity.  
III. Central  B cell tolerance 
 In the BM, B cells are ‘selected’ to continue to develop or not at the pre-B cell 
and immature B cells stages via any of three central tolerance mechanisms: receptor 
editing, deletion, or anergy (Melchers F. 1995, Rolink AG. 2001, Pieper K. 2013). B cell 
positive selection occurs when BCRs are exposed to self-antigens.   If the interaction 
between the receptor and the self-antigen is weak, the pre-B cell receives a signal that 
enables it to continue the development process (Melchers F. 1995, Rolink AG. 2001, 
Pieper K. 2013).  However, if the receptor strongly binds to the self-antigen, the pre-B 
cell undergoes receptor editing (Melchers F. 1995, Rolink AG. 2001, Pieper K. 2013).  
Receptor editing is the process of Ig gene rearrangement to attain a productive BCR 
and inhibit further rearrangement.  If receptor editing is unsuccessful, the B cell 
undergoes apoptosis and is negatively selected or clonally deleted from the B cell 
repertoire (Melchers F. 1995, Rolink AG. 2001, Pieper K. 2013).  Alternatively rather 
than clonal deletion, cells can become ‘anergic.’ Anergy is a state of non-
responsiveness that represents another important central tolerance mechanism 
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whereby a B cell can no longer be activated through its BCR.  Together, these B cell 
tolerance mechanisms aim to prevent autoreactivity by eliminating immature B cells that 
recognize self-antigen before they leave the BM.  If successful, only anti-microbial 
immature B cells leave the BM and migrate to the secondary lymphoid organs where 
they become functional mature B cells (Melchers F. 1995, Rolink AG. 2001, Pieper K. 
2013).   
IV. Peripheral B cell tolerance and maturation of peripheral B cell sub-populations 
  Immature B cells leave the BM and migrate to secondary lymphoid tissues, such 
as the spleen and lymph nodes for further maturation.  The spleen is a major secondary 
lymphoid organ and is divided into the red pulp, where the blood is filtered and iron 
recycled, and the white pulp, where a majority of the resident cells are lymphocytes 
(Nolte MA. 2004, Mebius RE. 2005, Pieper K. 2013).  Migration of immature B cells into 
the spleen is orchestrated by the chemokine CXCL13 produced by the stromal cells in 
the spleen.  High levels of CXCL13 receptor, CXCR5 (Pieper K. 2013), enables 
immature B cells to home to secondary lymphoid organs.    
In secondary lymphoid organs, B cells are arranged in follicles, or B cell zones, of 
the white pulp (Nolte MA. 2004, Mebius RE. 2005).  The marginal zone (MZ) divides the 
red and white pulp.  The MZ contains several distinct populations of macrophages, 
dendritic cells (DCs), as well as MZ B cells.  In mice, MZ B cells do not re-circulate and 
are thought to be vital in the maintenance of the MZ and other cell types that reside 
there (Nolte MA. 2004, Mebius RE. 2005).  
In summary, two major checkpoints filter out potentially autoreactive B cell 
subsets.  The first checkpoint occurs in the BM via receptor editing, clonal deletion and 
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anergy (Melchers F. 1995, Rolink AG. 2001, Pieper K. 2013) and in the periphery as 
these cells leave the BM as “transitional cells.”  The second checkpoint occurs in 
follicles called germinal centers (GC) that will be discuss in more detail in this chapter. 
Once a functional B cell is positively selected they can now move on to the next stage of 
development.  To ensure survival during this developmental stage, B cells require 
survival signals before they can differentiate into mature naïve B cells (“follicular) or the 
aforementioned MZ B cell (Pieper K. 2013). The major B cell subsets known to be prone 
to autoreactivity and under control of these two tolerance checkpoints will be discussed 
in more detail below. 
V. Transitional B cells 
 Immature B cells migrate from the BM to the periphery where they transition into 
functional mature B cells.  Several receptors expressed on the surface of ‘transitional’ B 
cells are used to track their maturation stage during migration to secondary lymphoid 
organs. Transitional (T1, T2, T3) B cells can be divided into subsets based on the 
surface expression of CD23, IgM, and the developmental marker AA4 (Allman D. 2001).  
T-1 cells are surface (s) sIgMhi, sIgDlow CD23low and are found in blood, BM and spleen; 
T-2 cells are sIgMhi, sIgDhi, CD23 and are found in the spleen (Allman D. 2001, Sims 
GP. 2005).  T-2 cells are thought to be derived from the T-1 cells (Allman D. 2001, Sims 
GP. 2005).  T-3 cells are reported to be an anergic splenic population that does not 
progress into the mature stage (Merrell KT. 2006, Vossenkamper A. 2011).   
There are both functional and phenotypic differences in human compared to 
murine transitional B cell subsets. Interestingly, all transitional B cell populations in mice 
were found to be non-proliferative in vivo (Allman D. 2001).  About 40 percent of 
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transitional B cells in human blood are autoreactive and do not enter the pool of mature 
functional B cells (Wardemann H. 2003, Meffre E. 2004).  A subset of transitional B cells 
in human blood was found to be similar to murine T-1 cells in terms of cell surface 
phenotype (Sims GP. 2005).  These circulating human T1 cells were identified by the 
following cell surface phenotype: CD38+, IgD+, CD27-, CD44low, CD24hi, CD21low, 
CD23low, IgMhi, and CD62low.  Unlike mouse T-1 cells, human transitional cells also 
express CD5 and CD43 (Sims GP. 2005). More recently, Suryani et al. described a 
subset of transitional cells characterized by the presence of CD21 (Suryani S. 2010).  
CD20+CD27-, CD10+ and CD21low B cells and CD20+CD27-, CD10+CD21hi B cells were 
isolated from peripheral blood, cord blood and spleen (Suryani S. 2010) (Sims GP. 
2005).  The authors found a difference between the frequency of CD10+ CD21low and 
CD10+CD21hi B cell subsets (Suryani S. 2010).  The CD21low cells were abundant in the 
human spleen and decreased in the peripheral blood, in which CD21hi B cells appeared 
in the highest frequency (Suryani S. 2010).  Whether CD21low or CD21hi B cell subsets 
were enriched in autoreactive B cells and contributes to autoimmunity remains to be 
determined. 
An additional human transitional subset has been characterized by the cell 
surface expression of CD24int, CD38int, IgD+, CD27-. These cells differentiate into 
mature B cells in vitro (Palanichamy A. 2009).  Interestingly, Palanichamy et al. found 
that this population was especially prevalent during reconstitution in patients after B cell 
depletion therapy (BCDT) and over time was replaced by mature naïve B cells 
(Palanichamy A. 2009).  This suggests that CD24int, CD38int, IgD+, CD27- B cells are at 
the late stages of being transitional B cells before differentiating into mature naïve B 
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cells.   
VI. Marginal Zone and Follicular B cells 
 B cell subsets are a result of differentiation or maturation, and B cell lineage 
commitment is dictated by several factors that operate together. Whether immature 
transitional B cells become MZ or follicular (Fo) cells depends in part on the strength of 
BCR signaling based on the interaction with self-antigens and Notch 2, a member of the 
NOTCH family (Pillai S. 2009). Murine B cells deficient for Notch 2 do not mature into 
MZ B cells, suggesting that both a weak BCR signal and Notch 2 induce MZ B cell 
development, while a strong BCR signal favors the development of Fo B cells (Pillai S. 
2009). Both MZ and Fo B cells reside in specialized compartments of the spleen and 
each possesses distinct functional capacities.  
In the spleen and other secondary lymphoid organs, the MZ is a distinct 
microanatomical location where immune cells become specialized to defend against 
pathogens.  The MZ is located next to the marginal sinuses, the sites of entry into the 
spleen for lymphocytes, macrophages, and DCs (Mebius RE. 2005).  The marginal 
sinus separates the white pulp from the red pulp.  Pathogens reaching the bloodstream 
are efficiently trapped in the MZ by macrophages that participate in an early response 
with MZ B cells (Mebius RE. 2005). Thus, the spleen is a diverse environment 
comprised of multiple types of lymphoid and non-lymphoid cells. 
B cells localize in specialize areas of the spleen and lymph nodes for further 
maturation and differentiation.  Immature B cells exiting the BM may arise as follicles, 
which are an aggregate of cells found in the white pulp of the spleen. Upon arrival in the 
spleen, immature transitional B cells are destined to become either Fo mature B cells or 
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MZ B cells (Cariappa A. 2007).  The Fo B cells exist in the follicles while MZ B cells 
reside in the MZ of the spleen where they encounter blood-borne pathogens (Cariappa 
A. 2007). Follicles are always adjacent to T cell zones, an arrangement that allows 
activated Fo B cells and activated T helper (Th) cells to migrate towards each other and 
interact at the interface (Pillai S. 2004, Pillai S. 2009). Once an immature B cell 
becomes a MZ B cell, the newly differentiated MZ B cell will migrate to a new location in 
the spleen.   
There are also functional distinctions between MZ and Fo B cells. MZ B cells are 
considered to be more “hyperactive” compared to Fo B cells in their processing and 
presentation of antigen and stimulation of T cells (Gunn KE. 2006, Pillai S. 2009). MZ B 
cells are non-circulating, self-renewing B cells that react rapidly to blood-borne 
pathogens and are major contributors to an early T-independent response (TI) (Cyster 
JG. 2000, Martin F. 2001). TI responses are important in defending against blood-borne 
infection that can lead to endotoxic shock (Cyster JG. 2000, Martin F. 2001).  Typically, 
MZ B cells rapidly develop into extra-follicular plasma cells that secret IgM within the 
first three days of a short-lived response (Gunn KE. 2006).  In addition to having a role 
in TI responses, MZ B cells can participate in T dependent (TD) responses (Martin F. 
2002, Phan TG. 2005).  Thus, MZ B cells are positioned in the spleen to rapidly respond 
to both TI antigens and TD antigens with great efficiency.   
 Fo B cells are mature B cells capable of mounting an immune response. T2 B 
cells primarily mature into Fo B cells that are responsible for long-lived Ab responses 
and the generation of long lasting immunological memory.  When Fo B cells encounter 
antigens, they proliferate and upregulate activation markers such as CD80, CD86, and 
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CD40 (Pillai S. 2004, Pillai S. 2009).  Fo B cells also process and present antigen in the 
context of major histocompatibility complex (MHC) class II (MHCII) to activate T cells 
(Pillai S. 2004, Pillai S. 2009). The interaction between Fo B cells and T cells may result 
in a GC reaction responsible for production of high affinity binding Ig that will be 
discussed in further detail below.     
VII.  Signaling through the B cell Receptor (BCR) 
 BCR signaling in the periphery is extremely vital to how a B cell responds to 
antigen. The BCR is examined early on in B cell development to determine its affinity to 
self-antigen. Upon engagement with antigen, membrane bound BCR transmits a 
cascade of signals in B cells that results in the activation of key proteins. The BCR is 
also non-covalently associated with a disulfide-linked heterodimer of CD79a (Igα) and 
CD79b (Igβ) (Campbell KS. 1990, Hombach J. 1990, Gold MR. 1991, Cambier JC. 
1994, Batista F. 2001, Packard TA. 2013).  Igα and Igβ contain immunoreceptor 
tyrosine-based activation motifs (ITAMs) in their cytoplasmic tails that are 
phosphorylated after activation of the BCR (Campbell KS. 1990, Hombach J. 1990, 
Gold MR. 1991, Cambier JC. 1994).  Phosphorylation of ITAMs initiates a signaling 
pathway in B cells that will culminate in the regulation of important regulatory genes.  
Two tyrosines within the ITAM motif by Src-family kinases (SFK), including Lyn, which is 
the predominant SFK expressed in B cells (Saijo K. and Adachi T 2003) are also 
phosphorylated. Lyn phosphorylation enables phosphorylation of other tyrosine kinases 
that contain SH2 domains, including spleen tyrosine kinase (Syk) (Kurosaki T. 1995, 
Rowley RB. 1995, Shiue L. 1995, Saijo K. and Adachi T 2003).  Upon Syk activation, 
the BCR signal is transmitted by a group of proteins associated with the adaptor protein 
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B-cell linker (Blnk, SLP-65). Once the multi-protein complex containing cytosolic and 
membrane-bound signaling intermediates adhere to the Blnk scaffold, this complex is 
referred to as the BCR signalosome (Fruman DA. 2000, Packard TA. 2013). Other key 
signaling molecules are activated downstream, including phosphatidylinositol 3-kinase 
(PI3K) and phospholipase Cγ2 (PLCγ2)(Fruman DA. 2000, Packard TA. 2013).  PLCγ2 
regulates activation of protein kinase C (PKC) and calcium flux.  This PI3K pathway is 
required for efficient activation of the Ser/Thr kinase Akt, which blocks apoptosis in BCR 
stimulated cells (Fruman DA. 2000, Packard TA. 2013). 
Other potential signaling molecules downstream of Syk include the mitogen-
activated protein kinase (MAPK) family, such as extracellular signal-regulated kinase 
(ERK), c-Jun NH-2-terminal kinase (JNK), and p38 MAPK.  In addition, BCR signaling 
potentially results in activation of transcription factors, such as nuclear factor of 
activated T cells (NFAT) and the ubiquitously expressed NF-kB (Tedder TF. 1997, Sada 
K. 2001).  These molecules, signaling via the BCR, are important regulators of cell 
proliferation, survival, and differentiation. 
VIII. Antibody production by B cells in health and autoimmunity 
 The ability of B cells to produce antigen specific Abs makes them key players in 
adaptive immunity. An Ab consists of two identical H chains and two identical L chains, 
both of which consist of a constant (C) and V region.  The V regions determine antigen 
specificity, while the C region determines effector function and Ig class.   B cell 
autoreactivity can arise when self-antigen specific, Ab producing B cells are allowed to 
escape immune tolerance mechanisms.  
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A. Antibody (immunoglobulin) subtypes 
 There are five major classes of immunoglobulins (Ig):  IgM, IgD, IgA, IgE, and 
IgG (Janeway CA. 2005, Mix E. 2006).  IgM exists as a pentamer and is the first Ig class 
generated by B cells; it also makes up the bulk of TI and natural Ab responses. IgD 
exists as a surface molecule and is not secreted.  IgA exist as dimers and are secreted 
to protect mucosal surfaces.  IgE is rarely present in its free form and participates in 
mast cell and eosinophil activation to protect against worms and other parasites.  IgG is 
the most abundant isotype found in plasma. There are four IgG subclasses (IgG1,IgG2, 
IgG3, and IgG4), each with distinct effector functions.   
With the exception of initial co-expression of IgM and IgD, multiple Ig classes are 
prevented from being expressed in a single cell at the same time via DNA splicing 
events(Honjo T. 2002, Okazaki IM. 2002).  During an antimicrobial response, B cells 
differentiate into IgM producing plasmablasts (PBs).  However, GC B cells may undergo 
class-switching to higher affinity Abs.   Once class-switch from IgM occurs, both IgM 
and IgD alleles are deleted from the genomic DNA and a single Ig class is expressed. 
This change is made via the process of class switch recombination (CSR), which relies 
on activated-induced cytidine deaminase (AID) (Honjo T. 2002, Okazaki IM. 2002).  B 
cells expressing certain Ig isotypes are aberrantly negatively or positively selected in 
autoimmune diseases.  How CSR contributes to the production of autoreactive B cells 
will be discussed in greater detail in the loss of peripheral tolerance section of this 
chapter.   
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IX.  B-T cell interactions  
 Thus far we have discussed the maturation of B cells and how they contribute to 
an adaptive immune response via the production of Abs.  This next section will discuss 
the integral connection between B cells and T cells to achieve an effective response to 
antigens.  One of the effector functions of B cells is the production of high affinity Abs.   
Abs produced to protein antigens require help from Th cells including T follicular helper 
(Tfh) cells (Crotty S. 2011).  In return, B cells provide co-stimulatory signals to activate T 
cells that further enhance the immune response. B and T cell interactions are important 
to help clear microbial antigens and provide the host with long lasting immunological 
memory.   
Once an activated B cell encounters an activated Th cell, an immunological 
synapse is formed between the antigen-MHC II complex and the TCR (Tarlinton D. 
1998, McHeyzer-Williams MG. 2003, Manser T. 2004). This B-T cell interaction results 
in the production of cytokines by T cells that directly influence B cell proliferation and 
differentiation.   
For efficient activation, both B cells and T cells require additional co-stimulation.  
The binding of CD40 expressed on B cells and CD40L (CD154) on T cells is essential 
for activation (O'Connor BP. 2003).  These types of ‘second signal’ interactions provide 
activation and stimulatory signals for both B cells and Th cells.  Second signal 
interactions in the GC produce high affinity Ab.  
A.  Germinal Center (GC) 
 In the GC high affinity Ab secreting plasma cells (PCs) and memory B cells 
(MBCs) are produced. GCs are transiently formed, dynamic sites of initial interactions 
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amongst B cells, Tfh cells, and follicular DCs (FDCs).  A major objective of the GC 
response is the generation of life-long protective immunity that ensures rapid and 
efficient immune responses to recurrent infections.    Both MBCs and PCs are products 
of GC reactions and represent a population of cells that display higher affinity receptors 
(Garside P. and Jenkins MK. 1998, Okada T. 2005, Hamel K. 2012).  
Another pivotal interaction for GC formation and maintenance is the binding of 
the B7 molecules CD80 and CD86 on B cells to CD28 and CTLA-4 on Th cells 
(McHeyzer-Williams MG. 1993, Tarlinton D. 1998, McHeyzer-Williams MG. 2003).  This 
is an important second signal necessary for efficient B and T cell activation. Multiple 
cell-bound and secreted factors are also vital in the stimulation of B cells by Th cells, 
particularly, the inducible co-stimulator (ICOS) and its ligand ICOS-L.  
GCs are sites of intense B cell proliferation, Ig class-switching recombination 
(CSR), somatic hypermutations (SHM), and affinity maturation (Garside P. and Jenkins 
MK. 1998, Okada T. 2005, Hamel K. 2012). GCs have a characteristic architecture that 
includes histologically distinct dark and light zones (McHeyzer-Williams LJ. 2001), 
(McHeyzer-Williams MG. 2003). The organization of both the dark and light zones is 
accomplished through the CXCR5-CXCL13 and CXCR4-CXCL12 chemokine gradients 
(Allen CD. and N. 2004). Centroblasts (activated proliferating B cells) present in the 
dark zone express CXCR4 where the ligand CXCL12 is abundant. Centroblasts rapidly 
proliferate through a cyclin D3-dependent mechanism and undergo SHM.  Centroblasts 
proceed as centrocytes into the light zone for selection:  competition for limited antigen 
and a default program for cell death account for selection at this point (McHeyzer-
Williams MG. 1993, McHeyzer-Williams MG. 1999, McHeyzer-Williams LJ. 2001, 
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McHeyzer-Williams MG. 2003).  The remainder of the B cells proliferate to form a region 
of IgD negative cells within the primary follicle (Hamel K. 2012),(McHeyzer-Williams 
MG. 1999). These IgD- B cells migrate to the T-B cell border in search of T cell help.      
  The BCR serves two major roles for B cell activation in GC.  First, it transmits 
signals intracellularly upon binding antigen. Second, the BCR delivers antigen to 
intracellular sites where it is degraded, returned to the B cell surface as peptides bound 
to MHC class II molecules, and presented to T cells (Tarlinton D. 1998, McHeyzer-
Williams MG. 2003, Manser T. 2004). This is an additional function of B cells that 
enhances the adaptive immune response but also autoimmunity by potentially activating 
autoreactive T cells.     
  Distinct signaling mechanisms via the BCR within the GC determine the fate of 
B cells.  Low BCR affinity or the loss of function of the BCR results in centrocyte 
apoptosis. By contrast, centrocytes whose BCR affinity is enhanced through SHM are 
selected to re-enter the cycle or differentiate into either a long-lived PC or MBC 
(McHeyzer-Williams MG. 1993, McHeyzer-Williams MG. 1999, McHeyzer-Williams LJ. 
2001, McHeyzer-Williams MG. 2003). A distinct feature of GC reactions is the 
production of B cell clones that have undergone Ig class-switching (CSR) and affinity 
maturation.  CSR is a process that irreversibly rearranges the H chain C region genes 
from IgM or IgD to IgG, IgA, or IgE (Stavnezer J. 2008).  As stated earlier, this 
mechanism is mediated by AID, an enzyme that is upregulated after B cells receive T 
cell help at the T-B border (Revy P. 2000, Pape KA. 2003).  AID is also required for 
SHM by proliferating centroblasts of the GC dark zone (Muramatsu M. and Y 2000, 
Peled JU. 2008).   Newly formed GC B cell clones with an enhanced capacity to bind 
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antigen are then selected for survival and differentiation through a process known as 
affinity maturation.  Affinity maturation was originally thought to be a result from the 
competition of newly formed GC B cell clones for limited antigen presentation by FDCs 
(Tarlinton DM. 2000).  GC B cells with higher-affinity for antigen out-compete lower 
affinity clones and receive survival signals through BCR stimulation.  However, recent in 
vivo studies contradict this model by suggesting the interaction between FDCs and GC 
B cells are unstable and do not promote prolonged signaling (Allen CD. 2007).   
Several molecular pathways dictate B cell trafficking and maturation within the 
GC. A pivotal transcription factor expressed in GC B cells is B cell lymphoma 6 (Bcl-6), 
a transcriptional repressor induced in B cells by IL-21 that functions to suppress DNA 
responses caused by double stranded DNA breaks arising from CSR and SHM 
(Cattoretti G. 1995, Dent AL. 1997, Ye BH. 1997).  Bcl-6 also inhibits B lymphocyte 
induced maturation protein 1 (Blimp-1), a transcription factor crucial for PC 
differentiation (Cattoretti G. 1995),(Shaffer AL. 2000).  In addition to Bcl-6, paired box 
protein 5 (Pax-5) is an important transcription factor in maintaining the identity of GC B 
cells, perhaps due in part to its repression of X-box binding protein 1 (XBP-1), which is 
up regulated upon Fo B cell activation and required for PC differentiation (Wakatsuki Y. 
1994, Calame KL. 2001, Iwakoshi NN. 2003).  The Epstein Barr virus-induced G-protein 
coupled receptor 2 (EBI2) has been described as having a role in the localization of B 
cells within the follicles (Pereira JP. 2009), (Gatto D. 2009).  EBI2 is up regulated on B 
cells after interacting with T cells and this signals the B cell to migrate to the 
perifollicular region (Pereira JP. 2009), (Gatto D. 2009). Down-regulation of EBI2 sends 
a signal for B cells to localize at the follicle center where they interact with FDCs and 
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establish GC (Pereira JP. 2009), (Gatto D. 2009).  Altogether, these proteins control the 
decision between an extrafollicular response versus generation of memory; their role in 
differentiation to PCs will be discussed below. Upon antigen activation, some of the 
activated B cells form foci outside the T cell zone (extrafollicular foci) and differentiate 
into short-lived Ab secreting cells (ASCs). ASCs may class switch but do not show signs 
of SHM (Hamel K. 2012),(McHeyzer-Williams MG. 1999).   
1. Plasma cells 
 GC B cells may differentiate further into either MBCs or pre-plasma cells or 
plasmablasts (PB).   An alternative fate of GC B cells is the terminal differentiation into 
long-lived PCs that secrete class-switched, SHM Ab (O'Connor BP. 2003).  Terminally 
differentiated PCs reside in the BM where they produce long-lived Ab that can provide 
life-long protection from invading pathogens. PCs are characterized by decreased 
expression of B cell-specific surface markers such as the BCR, CD19, CD20, CD21, 
MHC II and several others and increased CD38 and CD138 expression (O'Connor BP. 
2003).  PCs are rarely found in the peripheral blood of humans but are often observed 
in tissue such as the kidneys of lupus nephritis (LN) patients (Chang A. 2011).  The 
increased presence of PCs in the kidneys of LN patients is suggested to be locally 
produced by resident B cells, perhaps autoreactive B cells (Kinloch  AJ. 2014).     
Complex transcriptional control and Tfh cell interaction drive differentiation of PB 
and the terminal differentiation of PC. The down-regulation of Pax-5 leads to decrease 
Bcl-6.  The decreased expression of these proteins diminishes expression of Blimp-1, 
the master regulator of PC differentiation (O'Connor BP. 2003), (Calame KL. 2001) .  
Blimp-1 further represses Pax-5, Bcl-6, proliferation, and other B cell lineage genes, 
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while activating XBP-1 (Calame KL. 2001). XBP-1 is expressed at high levels in PCs 
(Reimold AM. 2001, Shaffer AL. 2004).    It is also an important mediator of one branch 
of the unfolded protein response-signaling pathway that responds to endoplasmic 
reticulum (ER) stress induced by the accumulation of unfolded proteins in the ER lumen 
(Todd DJ. 2009).  XBP-1 activation is crucial to the survival of highly secretory cells 
because of its ability to regulate every stage of the secretory process (Todd DJ. 2009).  
Importantly, XBP-1 induces the expression of many components of the multi-protein 
chaperone complex that binds and processes nascent Ab H chains (Todd DJ. 2009).  In 
addition, the transcription factor Interferon regulatory factor-4 (IRF-4) suppresses Bcl-6 
expression and may have a role in terminal PC differentiation (Sciammas R. 2006) .  
Long-lived PC differentiation is linked to the number of rounds of GC B cell division 
(Hasbold J. and PD. 2004).  The association between cell division and PC differentiation 
may also be due to increased levels of SHM with continued centroblast divisions and 
the tendency of higher affinity GC B cells to be selected for PC differentiation (Martinez-
Pomares L. 2007, Peled JU and Goodman MF 2008).  Tfh cell derived IL-4, IL-21 and 
CD40L also impact the quality of PC responses through direct stimulation of GC B cells 
(Reinhardt RL. 2009, Crotty 2011).   
Cells committed to the PC lineage leave the GC as pre-PC, or PBs (O'Connor 
BP. 2003).  A majority of PBs express CXCR4. Through its interactions with its ligand 
CXCL12, CXCR4 directs PBs to the BM where they terminally differentiate into PCs 
(Sciammas R. 2006), (Odendahl M. 2005, Kalia V. 2006) .  However, a subset of PBs 
express CXCR3 whose ligands, CXCL9 and CXCL10, are expressed at sites of 
inflammation.  Once CXCR3+ PBs arrive at sites of inflammation, they terminally 
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differentiate and become resident producers of Ab (Loetscher M. 1998).  Once formed, 
PCs can persist and secrete Ab for long periods and in some cases the lifetime of the 
individual (Kunkel EJ. 2003, Tsubaki T. 2005, Tschen SI. 2006).  Ongoing generation of 
PBs and long-lived PCs in extra-lymphatic lesional tissue may be prominent in states of 
autoimmunity. 
2. Memory B cells (MBCs) 
 In addition to PC, MBCs are also generated by a GC response and maintained in 
the periphery.  After leaving the GC, MBCs re-circulate in the periphery, where they can 
survive for decades in humans (Crotty S. 2003).  Upon re-encounter with cognate 
antigen, MBCs rapidly proliferate and differentiate into PCs secreting high affinity Abs 
(Crotty S. 2004).  
Several characteristics describe functional MBCs.  They are defined as antigen-
experienced, long-lived, IgD- B cells that have undergone somatic mutations of their Ig-
V region genes (Crotty S. 2004, Fecteau JF. 2006).  Human MBCs have been 
characterized in peripheral blood and tonsil. These cells are larger in size than naïve B 
cells and express higher levels of co-stimulatory and activation molecules such as 
CD80, CD86, and CD95, and decreased expression of the IgE receptor CD23 (Ehrhardt 
2005).  Functional analyses revealed that human and murine MBCs respond faster and 
more strongly than corresponding naïve B cells (Liu YJ. 1995, Tangye SG. 2003). 
The continued existence of MBCs depends on several important factors.  Their 
maintenance and survival rely on the persistence of antigen in secondary lymphoid 
organs.  Originally, it was reported that the presence of antigen on the surface of FDCs 
was essential for the preservation of MBCs (Gray D. 1988, Maruyama M. 2000, 
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Barrington RA. 2002).  Later Anderson et al found that antigen alone was not required 
for maintenance of MBCs (Anderson SM. 2006).   To elucidate the mechanism involved 
in maintaining MBCs long-term, several groups have studied specific proteins involved 
in MBC survival. In particular, in human tonsillar B cell populations, Mcl-1 and Bcl-x1 
proteins were found to be reduced in MBCs compared to GC B cells (Vikstrom I. 2010).  
In addition, the apoptosis-inducer protein Puma regulates human and murine MBC 
survival (Clybouw C. 2011).  Puma is up-regulated in vitro upon mitogenic activation in 
both human and mouse and Puma-deficient mice show an excess of antigen-specific 
MBCs (Clybouw C. 2011).   
Classically, cognate antigen and memory Th cells are thought to be required for 
activation of quiescent MBC (McHeyzer-Williams MG. 2003), (Kalia V. 2006), (Kindler V. 
1997).  However, there is data that show that polyclonal stimuli, specifically soluble 
cytokines produced by T cells, and CpG oligodeoxynucleotide (short single-stranded 
DNA molecules) can induce the proliferation and differentiation of human MBCs 
(Bernasconi NL. 2002), (Bernasconi NL. 2002). As well as stimulation with CD27 ligand 
(CD70) and IL-10 (Agematsu K. 1998) can stimulate MBC proliferation and 
differentiation.  
MBCs respond rapidly to activating stimuli.  In vitro, stimulation through the BCR 
leads to increased secretion of Ab by MBCs compared to naïve B cells. Unlike naïve B 
cells, MBCs differentiate into ASCs upon stimulation with anti-CD40, IL-2 and IL-10 and 
BAFF in the absence of antigen (Liu YJ. 1995, Tangye SG. 2003).  After stimulation, 
some MBCs proliferate while others differentiate into short-or long lived PCs 
(McHeyzer-Williams MG. 2003), (Kalia V. 2006), (Kindler V. 1997), (Crotty S. 2003), 
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(Tangye SG. 2003, Tarlinton D. 2006),(Tangye SG. 2003). MBCs also up-regulate co-
stimulatory molecules such as CD80/CD86 to activate T cells as well as MHC class II 
molecules for antigen presentation (Liu 1995).    
MBCs may play a prominent role in SLE.  However, our understanding of the role 
MBCs contribute to disease is impeded by the lack of specific surface markers to 
identify MBCs. Jacobi et al previously reported a subset of MBCs present in the 
peripheral blood of SLE patients characterized by the expression of CD95.  These cells 
lacked the “traditional” memory cell marker CD27 (CD27-95+) however, they are 
enlarged cells that express somatically mutated Ig H chain transcripts (Jacobi AM. 
2008).  Interesting, the frequency of CD27-CD95+ B cells significantly associates with 
disease activity including flares (Jacobi AM. 2008). Our lab previously reported a subset 
of MBCs characterized by high expression of the BCR-co-receptor CD19 and low 
expression of complement receptor CD21 (referred to as CD19hi). We found that this 
MBC subset was increased in patients with end stage renal disease (ESRD) due to SLE 
(Culton DA. 2007, Nicholas M. 2008). This particular population of MBCs will be 
discussed in more detail later in this chapter.  Thus, in addition to long-lived 
immunologic memory, MBC subsets that should contribute to adaptive anti-microbial 
immune reactions may mount autoreactive responses when critical self-tolerance 
mechanisms are not functional. 
X. Peripheral B cell tolerance mechanisms and autoimmunity. 
 Thus far we have described the role of B cells in a normal microbial response.  
However, as stated earlier, autoreactive B cells may lose tolerance to self-antigens 
resulting in the development of autoAbs producing PCs.  Therefore the ability to 
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regulate autoreactivity is an important mechanism to prevent autoimmunity.  This next 
section will discuss the role of peripheral B cell tolerance and what happens when 
regulatory mechanisms are compromised. 
B cell tolerance is essential for maintaining nonresponsiveness to thymus-
independent self-antigens such as lipids and polysaccharides.  It is also important in 
preventing the development of Ab responses to protein self-antigens.  As discussed 
earlier, central B cell tolerance mechanisms include receptor editing, deletion and 
anergy.  However, highly effective, autoreactive B cells may escape from the BM where 
they may encounter self-antigens in the periphery.  If a mature B cell recognizes 
autoantigens in peripheral tissues without specific Th cell help, the B cell may be 
functionally inactivated by anergic mechanisms or may die by apoptosis. 
Anergy is an important mechanism to maintain B cell tolerance to self-antigens.  
It is a state of functional hyporeactivity induced by antigen encounter at the 
development stage in the BM or by chronic antigen exposure in the periphery 
(Shlomchik MJ. 2008).  Anergy is likely dependent on the degree (or affinity) of antigen-
BCR engagement and studies show that anergy can occur when an immature B cell 
experiences an intermediate degree of engagement of the BCR (Shlomchik MJ. 2008).  
Unless specific counter costimulatory molecule signals are present, an anergic B cell 
can no longer be activated through BCR; thus it does not proliferate, up-regulate 
activation markers, or secrete Ab (Goodnow CC. 1988, Eris JM. 1994, Shlomchik MJ. 
2008).  Abrogation of effector function in anergic B cells is due to dampened signaling 
through the BCR as measured by decreased phosphorylation of substrates and 
decreased calcium flux (Cooke MP. 1994, Benschop RJ. 2001).  Anergic B cells have a 
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shorter half-life than naïve B cells (Fulcher DA. 1994), due in part to an increased 
dependence upon survival factors such as BAFF (Lesley R. 2004). 
Anergic B cells can be rescued by engagement of costimulatory molecules or 
TLRs on the B cell (Pieper K. 2013) (Chang NH. 2008), (Meffre E. 2011).  In addition, 
binding of foreign antigens to IgD combined with T cell help allows anergic B cells to 
become activated and enter into a GC reaction (Pieper K. 2013).  However, anergic B 
cells may be exposed to self-antigens in the GCs.  Once exposed to self-antigens in the 
GC, B cells are not selected into the pool of long-lived switched MBC or into the PC 
pool (Pieper K. 2013).  This is a crucial regulatory point that is essential to prevent the 
proliferation of autoreactive B cells.  
Although effective, peripheral tolerance mechanisms such as anergy and 
deletion by apoptosis may fail resulting in an autoimmune response.  B cells are 
considered central mediators in some autoimmune diseases, in particularly SLE.   In 
addition to Ab producers, B cells may produce cytokines and act as APCs that present 
antigen to activate autoreactive T cells.  The central role of B cells in SLE will be 
discussed below. 
XI.   Systemic lupus erythematosus  
 SLE is a chronic autoimmune disease characterized by the production of auto-
Abs to intracellular proteins and nucleic acids.  SLE is the prototypic systemic 
autoimmune disease characterized by multi-organ involvement. The prevalence of SLE 
in the United States ranges as high as 1.5 million with an incidence ranging from 1.8 to 
7.6 cases per 100,000 persons per year (Rus V. 2001).  SLE affects women more often 
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than men, at a ratio of about 10:1, with minority women being affected three times more 
often than Caucasians  (Rus V. 2001). 
A.  Etiology of SLE 
 The causes of SLE are unknown but believed to be linked to a combination of 
genetic, environmental, and hormonal factors.  The development of transgenic and 
knockout mice has improved our understanding of the interplay between genetic and 
environmental factors and specific genes have been linked to SLE in humans and in 
mice, as have various environmental exposures (Eroglu GE. 2002, Parks CG. 2002, 
Tsao BP. 2004, Mackay MA. 2006).  For instance, abnormalities in certain genes, such 
as those encoding HLA-DR2 (Eroglu GE. 2002), Fc gamma receptor (Fcγ) (Mackay MA. 
2006) and proteins of the complement system (Tsao BP. 2004) are associated with SLE 
in mice and human. While environmental exposures have been implicated in both 
development and progression (Parks CG. 2002), causative agents have not been 
identified.  Clearly both genetic and environmental factors are important in the 
development of SLE; monozygotic twin concordance for SLE is only about 25-50 
percent (Klippel JH. 2001, Manderson, 2004 #200), and no single environmental agent 
results in disease in all individuals. To date, the interaction between genes and 
environmental exposures remains an area of active investigation. In addition to 
immunogenetic and toxicology studies, studies examining immune mechanisms 
responsible for tissue destruction are underway (including those presented in this 
thesis). Investigation aimed at improving our understanding of SLE pathophysiology is 
urgently needed so that this devastating disease can be effectively prevented and/or 
treated. 
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B. Renal disease increases the risk of mortalities in SLE. 
 The development of glomerulonephritis (Lupus nephritis, LN) is a principle cause 
of morbidity and mortality in SLE according to the Lupus Research Institutes (LRI).  The 
classification of LN is crucial to the issue of patient care (See Table 1:1 LN 
Classification). Each class defines the degree of kidney damage. The classification of 
the kidney biopsies allows clinicians to follow standard protocols that provide the best 
treatment options for patients. Active LN is associated with a 30 percent decrease in 
creatinine clearance, proteinuria of greater than 1000 mg/day, and renal biopsies 
suggest gross inflammation (Duran-Barragan S. 2008, Uchida K. 2011). Despite 
aggressive therapy, 10 to 30 percent of patients with LN will develop ESRD according to 
LRI.  Patients diagnosed with ESRD will be placed on renal dialysis or require a kidney 
transplant.   
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Table 1.1 International Society of Nephrology/Renal Pathology Society (ISN/RPS) 
classification of lupus nephritis 2003.  
 
 
 
 
LN Class Definition 
Class I Minimal mesangial LN 
Class II Mesangial proliferative LN 
Class III Focal lupus nephritis 
Class IV Diffuse segmental (IV-S) or global (IV-
G) LN 
Class V Membraneous LN 
Class VI Advanced sclerosing LN 
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Ig (or Ab) – antigen complexes called immune complexes or ICs are found 
deposited in kidney glomeruli. Glomeruli are tiny filters in the kidneys responsible for the 
removal of excess fluid, electrolytes and waste taken from the bloodstream. ICs 
mechanically interfere with glomerular function by increasing local inflammatory 
conditions.  Currently, kidney biopsies that identify the degree of glomerular damage 
and IC deposition are considered the best analytic tool for diagnosing LN. However 
serial biopsy is invasive, and impractical as a disease monitoring/prognostication tool.  
An alternative approach may be the use of patient urine and this methodology will be 
discussed later in the chapter. 
The ability to follow and study patient disease status and progression into ESRD 
is hampered by a lack of tissue samples.   Currently several biomarkers exist to follow 
LN patients. Serum levels of anti-dsDNA, creatinine clearance, urine protein to 
creatinine ratios, proteinuria and complement levels are all used to follow disease 
activity.  The problem with these biomarkers is that they often lack sensitivity and do not 
afford differentiation between levels of renal activity and damage.  Therefore, new 
biomarkers and methods for detection would lead to improved outcomes for patients.   
C.  Treatments for SLE 
 Standard treatment for SLE includes steroids and other immuno-suppressive 
drugs.  Advanced treatments for SLE remain unattainable in large part due to our poor 
understanding of the disease process.  The effective use of B cell depletion therapy 
(BCDT) to treat SLE suggests B cells play a significant role in disease pathogenesis 
(Looney RJ. 2010, Kamburova EG. 2013). While additional progress in our 
 28
understanding of the immune pathology in SLE has led FDA approval of agents like 
Benlysta, (anti-BAFF therapy that effects B cell survival), varied responses in patients 
have led to diminished enthusiasm for this agent. Some SLE patients are poor 
responders to this type of therapy and other types of BCDT such as Rituximab, a 
human monoclonal Ab specific for CD20 expressed on the surface of B cells, increase 
the risk of severe infectious side effects that negatively impact quality of life.  Therefore, 
further research is required to identify specific immune targets and mechanisms so that 
viable therapies for SLE patients can be developed.   
D.  SLE pathology  
1. Autoreactive B cells in SLE and loss of B cell tolerance 
 Mouse models have contributed to our understanding of the pathogenesis of 
SLE. The most commonly used mouse strains that develop spontaneous disease 
include the F1 cross between New Zealand Black and New Zealand White (NZB/W) 
mice, MRL/lpr mice and BXSB/Yaa mice.  Multiple genes contribute to the development 
of SLE in NZB/W mice, including MHC and several non-MHC genes (Rottman JB. 
2010).  The MRL/lpr strain contains the loss of function lpr mutation in the gene for Fas.  
Without Fas-Fas ligand interactions, apoptosis of B and T cells does not occur, resulting 
in massive lymphoproliferation that contributes to SLE (Kono DH. 2007, Rottman JB. 
2010).  MRL/lpr mice develop skin lesions and nephritis similar to human disease.  SLE 
in mice closely resembles human SLE, and murine models provide a powerful tool to 
study and understand molecular mechanisms leading to disease pathogenesis.   
 Nuclear antigens are not restricted and remain to be elucidated in part because 
of the nature of the B cell responses that develop to these antigens or to the nature of 
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the antigens themselves. Studies indicate that apoptotic nucleosomes are the inciting 
immunogens in SLE and subsequent recognition of additional self-antigens by B cells 
via “epitope spreading” to histones and dsDNA (Herrmann M. 1998, Gaipl US. 2007).  
Other evidence suggests that the expression of an array of autoantigens on the surface 
of apoptotic blebs (Casciola-Rosen LA. 1994) and the defective clearance of apoptotic 
debris (Herrmann M. 1998, Gaipl US. 2007) leads to autoAb formation.  However since 
there are patients with anti-dsDNA Abs who do not display detectable levels of anti-
chromatin reactivity (Borchers AT. 2012), other mechanisms leading to anti-dsDNA 
reactivity are certainly important in the development of autoreactive B cells and 
autoAbs. 
High autoAb titers are found in SLE patients. In the majority of SLE patients, anti-
nuclear Abs (ANA) are found in the plasma and tissues (Tan EM. 1989).  The 
interaction of these autoAbs with their corresponding self-antigen leads to the formation 
of IC, which are deposited in vessels and kidneys, leading to aggressive inflammation 
and tissue damage that can result in total organ failure (Grootscholten C. 2003).  In 
addition to the presence of aberrant Abs, multiple B cell abnormalities have been 
associated with SLE, including B lymphopenia, hyper-responsiveness to activating 
signals, increased expression of activation markers, and an increased frequency of 
PBs, newly formed transitional B cells and MBCs (Jacobi AM. 2000) (Bijl M 2001) 
(Blaese RM 1980, Bishop GA. 2000, Bishop GA. 2001). However, abnormalities 
underpinning autoreactive B cell dysregulation remain unknown.  
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2. SLE patients have high plasma IFNα levels.  
  In addition to heightened autoAb titers, SLE patients also have an increased 
presence of Type I IFN in their plasma (Bekeredjian-Ding IB. 2005) (Berggren O. 2012).  
Patients with high IFNα levels develop more severe nephritis and a number of IFN-
inducible genes are associated with SLE. Moreover, people receiving therapeutic IFNα 
have developed SLE-like conditions (Hueber W. 2004, Hua J. 2006). The significance of 
the association between IFNα and SLE is further strengthened by experiments in 
murine SLE in which deletion of the IFNα receptor gene (ifnar) resulted in ameliorated 
disease (Hueber W. 2004, Means TK. 2005, Hua J. 2006). Type I IFN directly influences 
immune cells including B and T cells.  IFNα induces the differentiation of monocytes into 
DCs and can activate immature myeloid DCs (mDCs).  mDC mediate activation of 
autoreactive T cells and provides help to activate autoreactive B cells, thereby 
increasing the production of autoAbs (Means TK. 2005, Borchers AT. 2012). 
Several lines of evidence exist that show endogenous RNA or DNA in the form of 
ICs can induce IFNα production by plasmacytoid DCs (pDCs) in healthy controls 
(Lovgren T. 2004, Barrat FJ. 2005, Christensen SR. 2007).  RNA-containing ICs signal 
through TLR7, whereas DNA containing ICs signal through TLR9 (Lovgren T. 2004, 
Barrat FJ. 2005, Christensen SR. 2007). Increased expression of TLR7 and TLR9 on 
pDCs along with locally available self-antigens enhances the production of IFNα by 
pDCs.  The heightened accessibility of autoantigen is partly due to the inability of 
macrophages to effectively clear apoptotic debris. In this scenario, self-antigens will 
bind to autoreactive Abs forming highly effective ICs.  This in turn will activate pDCs via 
TLR7 and TLR9 resulting in an increase production of IFNα. Thus one option to develop 
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more effective therapies for SLE is by targeting autoreactive B cells to eliminate 
autoAbs.  
3. Identifying autoreactive B cells in SLE 
As stated earlier, several B cell abnormalities exist in SLE patients (Budman DR 
1977, Blaese RM 1980, Chan OT. 1999, Fecteau JF. 2006, Chang NH. 2008). These 
abnormalities are not attributable to a single subset of B cells, and, therefore do not 
identify autoreactive B cells.  This inability to distinguish autoreactive from non-
autoreactive B cells has impeded our understanding of the molecular mechanisms that 
results in the loss of tolerance in human SLE and whether autoreactive B cells reside in 
the kidney.  Studies of SLE peripheral blood have found distinct B cell subsets that 
correlate with disease activity. Wei et al found a novel population of B cells that lacked 
the expression of CD27 in the peripheral blood of SLE patients (Wei C. 2007).  They 
found this population significantly associates with higher disease activity, a history of 
nephritis and disease specific autoAbs (anti-dsDNA, anti-Sm).   Later, Jacobi et al found 
a subset of MBCs in the peripheral blood of some SLE patients that also significantly 
associated with disease activity including flares (Jacobi AM. 2008). This B cell subset 
was characterized by the expression of CD95 (CD27-CD95+).   
Overall, several studies have found that distinct subsets of peripheral blood B 
cells associate with disease activity.  The mechanisms of how these B cell subsets 
contribute to disease remains to be elucidated.   In addition, whether these subsets are 
found in the tissues and contribute to the local autoAb milieu has yet to be determined.  
Therefore, the ability to characterize and study tissue resident autoreactive B cells may 
enhance our understanding of the molecular mechanisms that results in the loss of B 
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cell tolerance.   Our lab previously identified an expanded B cell population in peripheral 
blood of SLE and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis 
patients (Culton DA 2007, Nicholas M 2008). These B cells exhibit high expression of 
CD19 and CD20 and low expression of CD21 (referred to herein as CD19hi). The 
CD19hi population is expanded in ~30 percent of SLE patients where it comprises an 
average 8-10 percent of peripheral blood B cells, but can comprise >50 percent of 
peripheral blood B cells in some patients (Culton DA. 2007, Nicholas M. 2008).  The 
presence of an expanded CD19hi B cell population in peripheral blood correlates with 
ESRD and neurological complications (Nicholas M. 2008), and high titers of certain 
autoAbs, including anti-Sm, a hallmark anti-ribonucleoprotein (RNP) autoAb of SLE 
(Nicholas M. 2008). Interestingly, the circulating anti-Sm B cells are CD19hi B cells and 
the anti-Sm titer correlates with the frequency of CD19hi B cells specific for Sm 
(Nicholas M. 2008). These data suggest that CD19hi B cells contribute to disease, and 
therefore, understanding the function of CD19hi B cells may provide insight into disease 
mechanisms.   
CD19hi B cells have an activated MBC phenotype.  Several receptors are up 
regulated during the B cell activation process including the death receptors, FAS 
(CD95), and programmed cell death-1 (PD1).  CD95 is expressed on the surface of 
many different cells and upon ligation with its ligand CD95L will signal the cell to 
undergo apoptosis (Kanemitsu S. 2002 , Li LH. 2009 , Manea ME. 2009 ). Naïve B cells 
exhibit only low levels of CD95 expression and cannot be killed by CD95L effector 
populations (Garrone P. and J 1995, Rothstein TL. 1995, Schattner EJ. and MK 1995).  
GC derived B cells have been shown to express elevated levels of CD95, to be 
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sensitive to CD95-induced apoptosis subsequent to CD40 engagement, and to be 
rescued from CD95-mediated apoptosis in the latter stages of their differentiation by Ab 
receptor engagement (Lagresle C. 1995, Mandik L. 1995, Watanabe D. 1995, Choe J. 
1996).  Such data suggest that CD95-CD95L interactions are an important factor in the 
elimination of autoreactive B cells. 
We hypothesized that CD19hi B cells are recently activated autoreactive B cells 
that are migrating to sites of inflammation.  This stems from previous data showing 
CD19hi B cells having an increased expression and frequency of CXCR3, a chemokine 
receptor that traffic cells to sites of inflammation (Nicholas M. 2008).  The authors also 
show that CD19hi/CXCR3+ B cells migrate towards it ligand, CXCL9 and CXCL10 
(Nicholas M. 2008). The significant correlation between having an expanded CD19hi B 
cell subset and ESRD suggests that CD19hi B cells have renal involvement.  Our model 
proposed that self-antigen reactivates the CD19hi MBCs which migrate to the kidneys 
due to high expression of CXCR3.  In the kidneys CD19hi B cells clonally expand, 
differentiate into PCs, and contribute to kidney inflammation via autoAb production. 
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Figure 1.1. CD19hi B cells are trafficking to sites of inflammation. 
Autoreactive CD19hi B cells are reactivated by self-antigen in the lymphoid tissues.  
Once reactivated CD19hi B cells will migrate to inflammatory sites such as the kidneys 
or CNS.  There we propose CD19hi B cells interact with CD4+ T cells (Tfh) to form GC.  
In GC the CD19hi B cells clonally expand and differentiate into PCs.    T, T cells; CNS, 
central nervous system; PCs, plasma cells. 
 
XII. SUMMARY OF DISSERTATION 
 In this PhD thesis, we examined the phenotypic and functional characteristics of 
B, T, and pDCs in the urine and blood from patients with SLE.  We propose that CD19hi 
B cells are autoreactive and contribute to the progression of ESRD.  To explore this 
hypothesis, we analyzed urine collected from SLE patients.  The data presented herein 
reveal differences in the presence of B, T, and pDCs in the urine. We found that 
increased frequency of PB/PCs and the number of CD4+ T cells in urine significantly 
correlated with SLE disease status.  The presence of an expanded CD19hi population in 
 35
LN patients further suggested a role for activated PBs in human SLE.  Further analyses 
of these cells and of additional tissue biopsies will provide insight into the 
immunopathology of the kidney in SLE.  
         Additionally, we found naïve and memory B cell subsets in the urine of rituximab-
treated SLE patients.  These data suggest that kidney-resident B cells are not 
necessarily depleted by rituximab.  Urine naïve and/or MBC populations in CD19hi 
patients included an expanded CD19hi B cell population.  We found that the CD19hi 
population was enriched in autoreactive B cells and these cells could be activated to 
become PCs, contributing to clinical relapse. 
           Finally, we show a significant relationship between IFNα/β levels and the 
frequency of pDCs in urine.  Our findings suggest that IFNα/β is derived from the 
kidneys where it may induce B cell to PB differentiation. Taken together, these data 
suggest a progression of changes in urine immune cells that correlates with worsening 
nephritis and the development of ESRD, particularly in patients with CD19hi PBs. 
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Chapter 2:  Immune cells and type 1 IFN in urine of SLE patients correlate with 
immunopathology in the kidney. 
 
 
 
2.1 Introduction 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease 
characterized by the production of autoantibodies to intracellular proteins and nucleic 
acids (Tan EM. 1982) (Hochberg  MC. 1997). The development of nephritis is a 
principal cause of morbidity and mortality in SLE, but the underlying 
immunopathological mechanisms of nephritis are still largely unknown. Insight into 
human LN comes principally from analysis of kidney biopsy tissue obtained at the time 
of diagnosis. However, the scope of the possible analysis on biopsy tissue is limited and 
serial biopsies are difficult to obtain due to the invasive nature of the procedure. Thus, 
by themselves biopsies are ill-suited for following the progression of nephritis within an 
individual to understand mechanism or to guide therapy. 
SLE patient urine may offer a window into inflammation in the kidney that would 
permit serial sampling and allow for more in depth phenotypic and functional analyses 
of immune cells. Mononuclear cells are present in the urine of patients with IgA 
nephropathy (Abdulahad WH. 2009) and detection of urinary lymphocytes is valuable in 
the diagnosis of kidney allograft rejection (Roberti I. 1995). T cells have been identified 
by flow cytometry in different forms of glomerulonephritis including IgA nephropathy, 
Henoch Schonlein purpura, and anti-neutrophil cytoplasmic autoantibody (ANCA) 
 37
vasculitis (Sakatsume M. 2001). Moreover, effector memory T cells are reported to be in 
the urine of SLE patients with active nephritis, and a high urine CD4 T cell count is 
associated with proliferative nephritis and may be useful in monitoring response to 
treatment (Dolff S. 2010, Enghard P. 2012)  (Enghard P. 2014).  
Analysis of kidney biopsy has revealed the infiltration of both myeloid and 
lymphoid cells, not all of which are known to be present in urine. Of these, B cells are of 
particular interest because they play a central role in LN through their ability to produce 
pathogenic autoantibodies (autoAbs), activate autoreactive T cells, and secrete 
cytokines (Shlomchik  MJ. 1994, Chan OT. 1999a, Chan OT. 1999b). B cells in the 
kidney of SLE patients are actively engaged in immune responses, including responses 
to kidney derived self-antigens (Sekine H. 2004). Kidney biopsies of LN patients have 
revealed that tubulointerstitial lymphocytic infiltrates exhibit either a diffuse distribution 
of B cells and plasmablasts (PBs) or plasma cells (PCs), or an organized pattern of T:B 
cell aggregates that can include germinal centers (GC) (Chang A. 2011). T:B 
aggregates and the GCs are associated with intrarenal B cell clonal expansion, somatic 
hypermutation, and antigen selection (Chang A. 2011). Consistent with this, B cells are 
in physical contact with TFH cells (Liarski VM. 2014). Sun et al. (Sun  C-Y. 2013) report a 
similar pattern of B cell tubulointerstitial infiltration in LN patients, although half of their 
patient cohort exhibited no B cell infiltration. Many of the kidney resident B cells bind 
vimentin, an abundant inflammatory protein produced in nephritic kidneys (Kinloch  AJ. 
2014). Thus, kidneys in LN patients are an active site of B cell activation, selection, and 
Ab production to kidney-specific antigens. 
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We previously identified an expanded B cell population in peripheral blood of 
SLE and ANCA-associated vasculitis patients that are enriched in autoreactive B cells 
(Culton DA. 2007), (Nicholas M. 2008). They exhibit high expression of CD19 and CD20 
and low expression of CD21 (referred to as CD19hi). CD19hi B cells comprise 1-3% of 
peripheral blood B cells in healthy individuals, but in ~30% of SLE patients they 
comprise an average of 8-10% of peripheral blood B cells with some patients reaching 
>20% (Culton DA. 2007), (Nicholas M. 2008). CD19hi B cells have a memory B cell 
phenotype, are somatically mutated, produce predominantly IgG, and are enriched in 
autoreactive B cells specific for Sm, a hallmark specificity of SLE (Culton DA. 2007), 
(Nicholas M. 2008). Patients with an expanded CD19hi population (CD19hi patients) 
differ in the repertoire of serum autoAbs compared to patients that lack an expanded 
CD19hi population (non-CD19hi patients). The expanded CD19hi population appears to 
be stable over time and correlates with end stage renal disease (ESRD) and 
neurological complications (Nicholas M. 2008). Thus, we propose that CD19hi and non-
CD19hi patients differ in the underlying mechanisms of disease, particularly in the kidney 
that might be reflected in urine cellular infiltrates. 
To determine whether there are differences in immune cells in the urine that 
correlate with disease status or the presence of an expanded CD19hi population, we 
examined urine from a cohort of 69 LN and non-LN patients. We report here that B and 
T cells and plasmacytoid dendritic cells (pDCs) are present in SLE patient urine. Our 
findings suggest a progression of changes in urine immune cells that correlates with 
worsening nephritis and the development of ESRD, particularly in CD19hi patients. In 
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addition to potentially providing insight into disease mechanism, urine immune cells may 
serve as biomarkers of disease progression and patient responsiveness to therapy. 
2.2  Materials and Methods 
2.2.1 HD and patient peripheral blood and urine samples. 
  Peripheral blood and urine samples were collected from 20 healthy donors 
(mean age: 37.3 years, range: 28-58, gender 16 females, 4 males) and 69 patients 
(mean age 41.2 years, range 22-77, gender 62 females, 7 males) with SLE and 5 
disease controls (5 ANCA); in some cases, the same healthy control or patient was 
used on multiple occasions or in multiple experiments. Patients were included in this 
study after informed consent in accordance with our institutional internal review board, 
and fulfilled at least four of the established American College of Rheumatology 1997 
revised criteria for SLE. Samples were gathered during routine clinic visits.   
Peripheral blood samples were collected into Vacutainer CPT tubes with sodium 
heparin (BD Biosciences) and sera and peripheral blood mononuclear cells (PBMCs) 
isolated per the manufacturer’s protocol. PBMCs were washed once with sterile 
phosphate buffered saline (PBS) before continuing with any protocol.  Urine samples 
were collected and supplemented with FCS (30% v/v) and processed as described 
before (Stachowiak J. 1998). Briefly, Ficol (GE) was added to the collected urine and 
centrifuged at 1600 rpms for 30 min at 4º C. Recovered mononuclear cells were 
resuspended in FACs buffer and used for flow cytometry analysis.  
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2.2.2 Cell surface staining and FACS analysis 
 For surface staining, cells were prepared as described above and stained on ice 
for 20 min and then washed twice with 1X PBS.  The Abs used were as follows: anti-
CD19APC, anti-CD19PAC BL, anti-CD19 PE-CY7, anti-CD20 APC-CY7, anti-IgD FITC, 
anti-IgG FITC, anti-IgM FITC, anti-CD38 PE-CY7, anti-CD3 PER CP, anti-CD4 APC, 
anti-CD4 PAC BL, anti-CD8 PAC BL, anti-CD21 PE, anti-CD303 PE, and anti-CD303 
FITC (Biolegend, San Diego CA).  To distinguish live cells, Pacific Orange was added at 
a concentration of 0.02 mg/ml to each sample and incubated at room temperature for 20 
min, after which each sample was washed three times with FACS buffer. 
2.2.3 WISH cell culture. 
  WISH cells, a human epithelial cell line (product no. CCL-25; American Type 
Culture Collection, Manassas, VA), were grown in minimum essential medium 
supplemented with L-glutamine (2 mM), HEPES (20 mM), penicillin (100 units/ml), 
streptomycin (100 ug/ml), and 10% fetal bovine serum at 37ºC in an atmosphere 
containing 5% CO2. To measure interferon regulated gene up regulation in patient 
plasma and urine, WISH cells were cultured at a density of 0.5 x 105/0.1 ml in 96-well 
flat bottom plates containing media alone, recombinant human IFNα (BioSource 
International, Camarillo, CA) at 100 units/ml (Hua J. 2006), or 50% donor plasma or 
urine.  After 6 hrs of incubation, WISH cells were lysed and stored at -70º C (Hua J. 
2006). 
2.2.4 Real-time quantitative PCR assay 
 RNA was extracted from each cell lysate using the RNeasy Mini Kit (Qiagen, San 
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Diego, CA) and 500 ng of RNA was reverse-transcribed to complementary DNA (c-
DNA) in a 20 µl reaction using iScript cDNA Synthesis Kit (Bio-Rad Laboratories, 
Hercules, CA). The cDNA obtained from each sample was diluted 1:60, and 2 µl was 
amplified in a 20 µl real-time quantitative PCR reaction using 10 µM forward and 
reverse primers and the 2x iQ SYBR Green Supermix (Roche laboratories).   
2.2.5 ELISpot assay 
 Anti-IgG and anti-IgM ELISpot protocols were described previously (Nicholas M. 
2008).  Briefly, 96-well filter plates were coated with anti-IgG or anti-IgM ( Bethyl 
Laboratories, Montgomery TX).  PBMCs from blood and immune cells from urine were 
resuspended in DMEM supplemented with 10%FBS, 100 U/ml Penicillin/Streptomycin 
(Gibco Invitrogen, San Diego CA), 40 mg/ml transferrin (BD Biosciences, San Diego, 
CA), and 0.01% β2-mercaptoethanol ( Gibco Invitrogen, San Diego, CA) and plated at 
2.5 x 104 to 5 x 105 cells in 200 ml/ well.  Each plate was incubated for 48-72 hrs at 
37ºC with 5% CO2.  The plates were then washed as previously described (Nicholas M. 
2008) and incubated with anti-human IgG-HRP Ab (Bethyl laboratories, Montgomery 
TX) overnight at 4ºC.  The plates were then developed with AEC substrate and read as 
previously described (Nicholas M. 2008).   
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2.3. Results 
2.3.1 B and T cells are present in patient urine. 
  To determine whether B and T cells are present in patient urine, we collected 
blood and urine from 20 healthy donors (HD) and 69 SLE patients. Twenty-eight of 
these patients were non-LN patients and 41 were LN patients. Three of the latter had 
progressed to ESRD. In addition, we collected blood and urine from 5 ANCA-associated 
vasculitis patients as disease controls that were matched with LN patients for serum 
creatinine levels to approximate similar kidney function. This lupus patient cohort 
averaged 41.2 years of age and was 90% female and 62% African American (Table 
2.1).   
Mononuclear cells from patient urine were Ficoll-purified to eliminate non-cellular 
debris and stained for B and T cell markers for FACS analysis. As shown in Fig. 2.1A 
and Table 2.2, CD19+ B cells and CD3+ T cells were present in urine of 64% and 80% of 
patients, respectively. Only 20% of patients had neither cell type. On average, T cells 
were present at a higher frequency than B cells, and CD8 T cells were present at a 
higher frequency than double negative (DN) and CD4 T cells (Fig. 2.1B). Moreover, T 
cells were often found in the absence of B cells, but B cells were always accompanied 
by T cells. No lymphocytes were found in HD urine, and only T cells were found in 
disease control patient urine (data not shown).  
LN and non-LN patients differed in the occurrence of urine lymphocytes. 
Lymphocytes were found in 61% (17 of 28) of non-LN patients and 93% (38 of 41) of LN 
patients (p= 0.0019; Fishers exact test) (Table 2.2). All 3 ESRD patients had B and T 
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cells in their urine. Thus, the prevalence of lymphocytes in the urine increases with the 
development of nephritis.  
2.3.2 SLE patients segregate into two subsets based on urine B cell phenotype. 
  To further analyze the B cells present in urine, we examined surface marker 
expression by FACS. Of the 44 patients with urine B cells, 23 had B cells that 
phenotypically resembled peripheral blood B cells. Most patients had a majority 
population of naïve B cells (CD19+, CD20+, CD21+, CD38+, IgD+, IgM+, and IgG-) (Figs. 
2.2A and 2.2B) with a minority population of switched memory B cells (CD19+ CD20+ 
CD38+/-, CD27+/-, IgD-, IgM+/-, and IgG+), although in 4 of 14 patients (28%) the switched 
memory B cells constituted the majority (Fig. S2.1). We refer to these B cells as 
naïve/memory B cells. Patients with a high frequency of CD19hi B cells in peripheral 
blood also had a similarly high frequency of CD19hi B cells in their urine (Fig. 2.2A), and 
the frequency of CD19hi B cells in urine and peripheral blood correlated significantly 
(Fig. 2.2C). Two patients were an exception to this; they had very high frequencies of 
urine CD19hi B cells, but very low frequencies of peripheral blood CD19hi B cells. 
Interestingly, both were CKD patients. 
  The urine B cells in the remaining patients (21 of 44) had a PB or PC phenotype. 
They were CD19low, CD20-, CD21-, and CD38hi and did not express IgD, IgM, or IgG 
(Fig. 2.2D and 2.2E). Importantly, these cells spontaneously secreted IgG, as 
determined by IgG ELISpot (Fig. 2.2F). Among the patients analyzed, we did not detect 
IgM-secreting cells. We refer to the Ig-secreting urine B cells as PB/PCs. As expected, 
the urine naïve/memory B cells did not secrete Ab of either isotype (Fig. 2.2F). 
Surprisingly, no patients had a mixture of naïve/memory B cells and PB/PCs in their 
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urine. Patients with urine naïve/memory and PB/PCs did not differ in treatment regimen 
(Table 2.3).  
2.3.3 Urine B cells are likely of kidney origin.  
 Urine B and T cells could derive from several sources, such as the genitourinary 
tract, peripheral blood, and kidney. However, no patients at the time of urine collection 
were known to have a urinary tract infection and there was no evidence of red blood 
cells in the urine samples analyzed. Moreover, a direct peripheral blood origin could not 
account for the large subset of patients with urine PB/PCs, as analysis of paired 
peripheral blood and urine from individual patients indicated that PB/PCs were a minor 
component of peripheral blood B cells in these patients (Fig. 2.2D and 2.2E, and data 
not shown). Strikingly, four patients had undergone B cell depletion therapy with 
rituximab, and in each case, despite the lack of B cells in peripheral blood, 
naïve/memory B cells were present in urine (Fig. 2.3A and 2.3B). Thus, for these 
patients urine B cells cannot have derived directly from peripheral blood. Although we 
cannot exclude a direct peripheral blood origin for every patient, these observations, 
along with the finding that B cells and PB/PCs are present in kidney biopsy tissue from 
LN patients (Chang A. 2011, Sun  C-Y. 2013), suggest that urine B cells derive from 
kidney resident populations.  
2.3.4 The presence of PB/PCs in urine correlates with more severe LN. 
  The frequency of patients with no B cells, naïve/memory B cells, or PB/PCs in 
urine was not significantly different between CD19hi and non-CD19hi patients (Table 
2.4). However, 90% of patients with urine PB/PCs were LN patients (Table 2.5; 
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p=0.0016; Fishers exact test) and all 3 ESRD patients had urine PB/PCs. Thus, the 
presence of PB/PCs in the urine is associated with LN.  
An association between urine B cell phenotype and glomerulonephritis class 
(ISN/RPS 2003 classification and WHO classification of LN) further suggested a link 
between urine B cells and LN. Eight-times as many patients with urine PB/PCs 
presented with proliferative nephritis (class III or IV, with or without V) as membranous 
or non-proliferative nephritis (class I, II or V) (Table 2.7; p<0.0001). In contrast, 4.5-
times as many patients with no urine B cells presented with non-proliferative or 
membranous nephritis than proliferative nephritis. Patients with urine naïve/memory B 
cells tended to present more often with non-proliferative nephritis than proliferative 
nephritis, although the difference was not significant. Thus, urine B cell phenotype may 
reflect kidney pathology.  
  As a further measure of LN severity, we determined the estimated glomerular 
filtration rate (eGFR). As expected, patients with the lowest eGFRs were LN patients 
(Fig. 2.4A). Importantly, all LN patients with a low eGFR (<30) had urine PB/PCs and 
were CD19hi patients (Fig. 2.4B and 2.4C). Conversely, all but one patient with an eGFR 
>40 had urine naïve/memory B cells or no B cells, and they included CD19hi and non-
CD19hi patients. Thus, CD19hi patients with urine PB/PCs appear more likely to develop 
a substantial loss of kidney function than patients with urine naïve/memory B cells or no 
urine B cells. 
Finally, we determined whether B cell phenotype correlated with active disease, 
defined as a SLEDAI score of 8 or above. We found that the presence of urine PB/PCs 
significantly correlated with active disease (Table 2.7; p=0.0153). Patients with no urine 
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B cells or urine naïve/memory B cells were skewed toward inactive disease, although 
this did not reach statistical significance. In agreement with the significant association 
between urine PB/PCs and LN, we find that LN patients were more likely to have active 
disease than non-LN patients (Table 2.7; p=0.0244). CD19hi and non-CD19hi patients 
did not differ in disease activity (Table 2.7). Altogether, we find that patients with urine 
PB/PCs are more likely to have proliferative glomerulonephritis with a substantial loss of 
kidney function and to have active disease.  
2.3.5 CD19hi SLE patients with urine PB/PCs had high urine IFNα/β levels and a 
high frequency of urine pDCs. 
 IFNα/β promotes PB differentiation (Jego G. 2003, Mathian A. 2011), and since 
many SLE patients have high circulating IFNα levels and exhibit an IFN signature 
(Bengtsson AA. 2000, Weckerle  C. 2011) (Baechler EC. 2003) (Kirou KA. 2004), we 
hypothesized that this would contribute to the presence of urine PB/PCs. To test this, 
we assessed IFNα/β levels in patient urine and plasma using a reporter cell bioassay. 
Based on the upregulation of three IFNα/β responsive genes, IFIT-1, MX1 and PKR, we 
inferred elevated IFNα/β levels in the urine of most patients with urine PB/PCs, and 
comparatively low levels in patients with urine naïve/memory B cells (Fig. 2.5A and Fig 
S2.2A and S2.2B). Consistent with a possible difference in disease mechanism, CD19hi 
and non-CD19hi patients differed significantly in IFNα/β levels; many CD19hi patients 
had elevated IFNα/β in both the plasma and urine, whereas non-CD19hi patients had 
uniformly low levels in plasma and urine (Fig. 2.5B and S2.2C and S2.2E). Interestingly, 
the up regulation of MX1 and PKR by paired plasma and urine samples from the same 
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individual correlated significantly (Fig. S2.2D and S2.2F), whereas the up regulation of 
IFIT1 was anti-correlative (Fig. 2.5C), suggesting a possible difference between plasma 
and urine in the IFNα/β subtypes present.  
pDCs are the major producers of IFNα/β in SLE (Bekeredjian-Ding IB. 2005, 
Berggren O. 2012), and therefore we determined whether pDCs were present in the 
urine of SLE patients. pDCs were identified by BDCA2 (CD303) expression (Fig. 2.5D) 
and, consistent with earlier reports (Fiore N. 2008, Tucci M. 2008) (Cederblad B. 1998, 
Blomberg S. Eloranta ML. 2001), were present at low frequency in the peripheral blood 
of SLE patients relative to HDs (Fig. 2.5E). pDCs were detectable in urine of all patients 
that had urine PB/PCs and many patients with urine naïve/memory B cells, although the 
frequency of urine pDCs was significantly higher in the former compared to the latter 
(Fig. 2.5E). No pDCs were present in urine of patients that lacked urine B cells 
altogether (data not shown). Similarly, urine pDC frequency differed significantly 
between CD19hi and non-CD19hi patients with only CD19hi patients having detectable 
pDCs (Fig. 2.5F). Interestingly, the frequency of pDCs in urine was commensurate with 
urine IFNα/β levels (Fig. 2.5G) suggesting local production of IFNα/β in the kidney by 
resident pDCs or by pDCs in the urine. Thus, IFNα/β and pDCs are present in the 
patient urine, but only in CD19hi patients, and predominantly in patients that have urine 
PB/PCs. 
IFNα is a major driver of SLE and high levels correlate with nephritis (Bengtsson 
AA. 2000, Baechler EC. 2003, Bekeredjian-Ding IB. 2005, Berggren O. 2012). We found 
that plasma IFNα/β levels in non-LN and LN patients were not different (Fig. 2.5H).  The 
frequency of peripheral blood pDCs in non-LN and LN patients was significantly lower 
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than HDs (Fig. 2.5I). In urine of non-LN patients, IFNα/β levels were not different from 
those in HDs, and pDCs were virtually absent (Fig. 2.5H and 2.5I). In contrast, LN 
patients had high levels of IFNα/β and a high frequency of pDCs in their urine (Fig. 2.5H 
and 2.5I). Thus, urine IFNα/β and pDCs occur primarily in CD19hi LN patients that have 
urine PB/PCs.  
2.3.6 Urine T cells differ between LN and non-LN patients.  
 T cells play a major role in SLE (Shlomchik MJ. 2001, Apostolidis SA. 2011) and 
are present in kidneys and urine of LN patients (Dolff S. 2010, Enghard P. 2012, Dolff S. 
2013, Sun  C-Y. 2013, Kinloch  AJ. 2014) (Enghard P. 2014), therefore we determined 
whether there were T cell differences between patient subsets. The percentage of T 
cells in peripheral blood was low in SLE patients compared to HDs, and significantly 
lower in LN patients than in non-LN patients (Fig. S2.3A). In contrast, the percentage of 
T cells in urine was similar in LN and non-LN patients, although the range varied 
considerably (Fig. S2.3A). However, they were predominantly CD4 T cells in LN 
patients and predominantly CD8 T cells in non-LN patients. Thus, LN patients have a 
high CD4:CD8 ratio (>1), while non-LN patients have a low CD4:CD8 ratio (<1) (Fig. 
2.6A and S2.3B and S2.3C).  
The difference in CD4:CD8 ratios also correlated with urine B cell phenotype. 
Patients had a similar frequency of T cells in their urine regardless of the presence or 
absence of urine B cells or urine B cell phenotype (Fig. S2.3D). However, patients with 
no B cells and most patients with urine naïve/memory B cells had a low frequency of 
CD4 T cells and a high frequency of CD8 T cells compared to patients with urine 
PB/PCs (Fig. S2.3E and S2.3F). Thus, patients with urine naïve/memory or no B cells 
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had a CD4:CD8 ratio <1, while patients with urine PB/PCs had a CD4:CD8 ratio >1 (Fig. 
2.6B). A similar difference was evident between non-CD19hi and CD19hi patients; most 
non-CD19hi patients had a low frequency of CD4 T cells and a high frequency of CD8 T 
cells in their urine (Fig. S2.3G-I) and consequently had a CD4:CD8 ratio <1, while most 
CD19hi patients had the opposite pattern and a CD4:CD8 ratio >1 (Fig. 2.6C and Fig. 
S2.3G-I). Thus, the urine CD4:CD8 ratio correlated with urine B cell phenotype, patient 
subset (CD19hi or non-CD19hi), and LN. This change in CD4:CD8 ratio was due to an 
increase in the number of urine CD4 T cells (Fig. S2.3J-L) and a decrease in the 
number of CD8 T cells (Fig S2.3M-O). Consistent with the significant correlation of a 
high urine CD4:CD8 ratio with urine PB/PCs and LN, the high CD4:CD8 ratio correlated 
with active disease (SLEDAI>8) (Fig. 2.6D). 
The frequency of DN T cells in peripheral blood of SLE patients is reported to be 
elevated compared to healthy individuals (Dean GS. 2002, Crispín JC. 2008), and this 
was true of our patient population (Fig. S2.4A). We observed no differences in the 
frequency of DN T cells in peripheral blood between LN and non-LN patients, or 
between CD19hi and non-CD19hi patients (Fig. S2.4A and S2.4C). Neither did we 
observe a difference in the frequency of DN T cells in peripheral blood between patients 
according to their urine B cell phenotype (Fig. S2.4B). However, we observed 
differences among patients of these SLE subpopulations in the frequency of urine DN T 
cells (Fig. S2.4A, B, and C). LN patients had a higher frequency of urine DN T cells than 
non-LN patients in agreement with their presence in LN kidneys (Crispín JC. 2008). In 
addition, CD19hi patients had a higher frequency of these cells in urine than non-CD19hi 
patients, and those patients with urine PB/PCs had a higher frequency of urine DN T 
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cells than those with urine naïve/memory B cells or no urine B cells. In each case the 
higher frequency can be attributed to an increase in DN T cell number (Fig. 2.6E-G). 
Consistent with a pathogenic role for DN T cells in nephritis (Apostolidis SA. 2011), we 
observed a positive correlation between urine DN T cell number and disease activity 
(Fig. 2.6H).   
2.4. Discussion 
 Improvement in our understanding of the immunopathology of LN is impeded by 
the difficulty in acquiring serial kidney biopsy samples and the inherent limitations in 
their analysis. In an effort to overcome these problems, we examined the urine of SLE 
patients to determine whether immune cells of kidney origin are present and whether 
their presence correlates with kidney pathology and disease status. We report here that 
B cells, T cells, and pDCs are present in patient urine, are likely of kidney origin, and 
are amenable to FACS and potentially functional analysis. Our findings suggest that 
they represent kidney resident populations, and that analysis of urine immune cells can 
provide insight into the immunopathology of the kidney in SLE and may be useful as 
biomarkers to guide patient therapy and to aid in clinical trials.  
Based on urine B cell phenotype, patients segregate into 2 groups of roughly 
equal sizes; patients in the first group have urine naïve/memory B cells, while those in 
the second group have urine PB/PCs. B cells of either type are unlikely to be of direct 
blood origin; analysis of paired blood and urine from each patient indicates that PB/PCs 
comprise a small subset of peripheral blood B cells, and thus by this scenario would be 
expected to be accompanied by a larger number of naïve/memory B cells. Similarly, 
naïve/memory B cells were present in the urine of four rituximab-treated patients that 
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lack peripheral blood B cells altogether, ruling out a direct blood origin for these 
patients. In contrast, B cells and PB/PCs are present in the kidneys of LN patients 
(Chang A. 2011), (Sun  C-Y. 2013), and as discussed below, patients with urine 
naive/memory B cells and urine PB/PCs differ in class and severity of nephritis 
suggesting that urine immune cells reflect the immunopathology of the kidney. Thus, 
although we cannot formally exclude other origins, we suggest that urine naïve/memory 
B cells and PB/PCs derive from the kidney, and therefore, that they represent kidney-
resident B cell populations.  
The presence of urine naïve/memory B cells in rituximab treated patients is 
particularly noteworthy, since it suggests that kidney-resident B cells are not necessarily 
depleted by rituximab. This is consistent with previous findings that some B cell subsets 
are resistant to depletion (Kamburova EG. 2013) (Davies RJ. 2013) (Thaunat  O. 2008). 
The urine naïve/memory B cell population in CD19hi patients includes an expanded 
CD19hi B cell population, implying that CD19hi B cells are present in the kidney. The 
CD19hi B cell population in peripheral blood is enriched in autoreactive B cells (Culton 
DA. 2007) (Nicholas M. 2008), and, assuming that this population in the kidney is 
similarly enriched, the inability of rituximab to deplete them could contribute to the lack 
of efficacy in clinical trials (Thaunat  O. 2008, Davies RJ. 2013, Kamburova EG. 2013). 
In addition, PB/PCs lack CD20 expression, and therefore, cannot be depleted by 
rituximab. Because they likely secrete autoAbs (Espeli M. 2011) (Sekine H. 2004, 
Kinloch  AJ. 2014), their persistence could be another factor in clinical relapse. 
Lymphocytes are present in urine of nearly all (~90%) LN patients, but present in 
urine of only 60% of non-LN patients. Thus, lymphocytes could appear in patient urine, 
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and by implication are present in the kidney, prior to the development of clinical 
nephritis and therefore urine lymphocytes may identify patients at risk of developing 
nephritis. This would be significant because ~60% of SLE patients develop LN within 
the first year of diagnosis, and to identify those patients most likely to develop nephritis 
could guide therapy to prevent the onset of nephritis. A longitudinal study of non-LN 
patients will be required to determine whether urine lymphocytes can serve as a 
biomarker of impending nephritis.  
Urine B cell phenotype is associated with kidney immunopathology. Nearly all 
patients (16 of 18) with urine PB/PCs have LN (p=0.0016; Fishers exact test), and with 
only 2 exceptions, these LN patients present with proliferative nephritis (p<0.0001; 
Fishers exact test). In contrast, LN patients that lack urine B cells present predominantly 
with non-proliferative nephritis. LN patients with urine naïve/memory B cells present with 
either. In addition, urine PB/PCs correlate significantly with a low eGFR and active 
disease. Moreover, all three ESRD patients have urine PB/PCs. Thus, urine PB/PCs are 
associated with proliferative nephritis and a significant loss in kidney function, 
suggesting that urine B cell phenotypic analysis could be useful in following changes in 
kidney pathology and to identify patients at risk for significant loss of kidney function and 
eventual development of ESRD.  
T cell phenotype also appears to reflect kidney immunopathology. Urine T cells 
from non-LN patients exhibit a low CD4:CD8 ratio, whereas LN patients exhibit a high 
CD4:CD8 ratio (p=0.0012). This shift is attributable to an increase in urine CD4 T cells 
and a decrease in urine CD8 T cells (Fig. S2.3). LN patients also have a greater number 
of DN T cells in urine (Fig. 2.6), which likely reflects their infiltration of the kidney 
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(Crispín JC. 2008). DN T cells produce IL-17 and are implicated in immunopathology of 
LN kidneys (Apostolidis SA. 2011).  The increase in CD4 T cell numbers in the urine is 
consistent with previous reports (Enghard P. 2012, Enghard P. 2014). However, others 
have reported an increase in CD8 T cells in urine of active LN patients (Dolff S. 2010, 
Dolff S. 2013), which we do not see, possibly due to differences in patient 
demographics. The increase in urine CD4 T cells may reflect the infiltration or 
expansion of CD4+ TFH cells that is seen in LN kidneys biopsies (Liarski VM. 2014). TFH 
promote B cell activation in germinal centers and extrafollicular foci (Vinuesa  CG. 
2010), and, since urine PB/PCs are associated with a high CD4:CD8 ratio, they may 
facilitate PB/PC differentiation in LN patient kidneys. In support, kidney TFH cells are in 
intimate contact with B cells (Liarski VM. 2014). Alternatively, this switch may be 
indicative of an expansion or infiltration of other CD4 T cell populations, such as TH17 
cells. They are expanded in peripheral blood of SLE patients and infiltrate the kidney 
(Crispín JC. 2008) (Dean GS. 2002).  Moreover, TH17 cells are implicated in kidney 
pathogenesis and can increase B cell activation, Ab production, and Ig class switch 
(Doreau A. 2009, Mitsdoerffer M. 2010).  DN T cells produce IL-17 and may also 
contribute to PB/PC differentiation, since they infiltrate the urine of patients with 
PB/PCs, and DN T cells from SLE patients can induce autoAb production as efficiently 
as CD4 T cells (Shivakumar S. 1989). Thus, we speculate that the increase in urine 
CD4 T cells and DN T cells reflects a shift in disease pathology that includes increased 
local autoAb production by kidney resident B cells and triggers a switch from the 
infiltration of naïve/memory B cells into the urine to PB/PCs. A better understanding of 
what this shift to CD4 T cell dominance and higher numbers of DN T cells means to the 
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immunopathology in the kidney will require a longitudinal study and subset analysis of 
these T cells.  
A significant finding from this study is the presence of IFNα/β and pDCs in patient 
urine. Either could come from the blood, as patients that have IFNα/β in urine also show 
evidence of high IFNα/β levels in their plasma (Fig. 2.5A and B), and pDCs are present 
in peripheral blood, albeit at a lower frequency than in HDs (Fig. 2.5E and Fig. 2.5F 
(Fiore N. 2008, Tucci M. 2008) (Cederblad B. 1998, Blomberg S. Eloranta ML. 2001). 
However, while MX1 and PKR up regulation by paired urine and plasma samples from 
SLE patients are positively correlated (Fig. S2.2D and F), the induction of IFIT1 up 
regulation is negatively correlated (Fig. 2.5C), suggesting a difference in IFNα/β 
subtypes between patient urine and plasma, inconsistent with a blood origin for urine 
IFNα/β. Along these lines, the frequency of urine pDCs, but not plasma pDCs, 
correlates positively with IFIT1 (Fig. 2.5G and data not shown) suggesting that urine 
pDCs are at least partly responsible for the presence of IFNα/β in urine. Since pDCs are 
present in LN kidneys (Fiore N. 2008), we suggest that the most likely source of urine 
IFNα/β are kidney-resident pDCs, of which those in the urine are representative.  
The presence of urine PB/PCs is significantly associated with the IFNα/β and 
pDCs in urine. The IFNα/β produced by pDCs promotes B cell to PB differentiation and 
pDCs also produce IL-6 that drives PB to PC differentiation (Krug A. 2001, Hochrein H. 
2002, Proietto AI. 2004). Thus, kidney resident pDCs could promote PB/PC 
differentiation. Beyond the effect on B cells, pDC-produced pro-inflammatory cytokines 
have multiple effects on adaptive and innate immune cells and can activate and 
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damage kidney endothelial cells directly (Fiore N 2008). These pro-inflammatory effects 
may account for the association of urine pDCs with proliferative nephritis and ESRD. 
We show here that although both CD19hi and non-CD19hi patients develop LN, 
CD19hi patients develop more severe loss of kidney function, as indicated by their low 
eGFR (Fig. 2.4). This is consistent with our previous finding that CD19hi patients are 
more likely to develop ESRD than non-CD19hi patients (Nicholas M 2008) and the 
finding that all three ESRD patients analyzed here are CD19hi. CD19hi and non-CD19hi 
patients do not differ in the proportion of patients that have urine naïve/memory B cells, 
PB/PCs, or no B cells suggesting that the more severe kidney disease in CD19hi 
patients is not secondary to a greater likelihood of having PB/PCs in the urine. 
However, only CD19hi patients have high IFNα/β levels in their plasma and, more 
importantly, high urine IFNα/β levels and a high frequency of urine pDCs (Fig. 2.5B and 
F and Fig S2.2C and E). Moreover, CD4 and DN T cells are present in urine at greater 
numbers in CD19hi patient urine.  Thus, a difference in the frequency of pDCs, CD4 T 
cells, and DN T cells all of which can produce pro-inflammatory cytokines may account 
for the development of more severe nephritis by CD19hi patients and their greater 
likelihood of progressing to ESRD.  
It is unclear why only CD19hi patient’s exhibit high IFNα/β levels in plasma and 
urine and a high frequency of pDCs in the urine. One possible explanation is that it is 
caused by the unique autoantibodies produced by these patients. The hallmark 
specificities of CD19hi patients are to RNA-associated antigens such as Sm (Culton DA 
2007), which are likely produced by PCs derived from CD19hi B cells themselves, since 
we have previously shown that anti-Sm B cells are enriched in the CD19hi B cell subset 
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(Nicholas M 2008). RNA containing immune complexes are more potent inducers of 
IFNα/β secretion by pDCs owing to the engagement of TLR7 than those containing 
DNA that engage TLR9 (Eloranta ML. 2009, Berggren O. 2012).   Thus, the unique 
autoAb repertoire of CD19hi B cells may be highly effective in promoting pDC activation 
and IFNα/β secretion. This could account for the higher levels of IFNα/β in plasma and 
urine and the higher frequency of pDCs in the urine.  
Altogether, these data suggest a model in which the development of LN and 
progression to ESRD is reflected in a progressive change in immune cells in urine. We 
propose that T and B cells first appear in the urine before clinical evidence of nephritis. 
At this early stage, the urine B cells are naïve/memory B cells and the T cells are 
predominantly CD8+. Over time, patients with urine lymphocytes develop nephritis and 
in some, the urine naïve/memory B cells are replaced by PB/PCs. In CD19hi patients 
this switch to PB/PCs may be due to IFNα/β production by pDCs in the kidney caused 
by the presence of RNA-associated immune complexes, in conjunction with the 
increased access to T cell help, as suggested by the increase in CD4 and DN T cells in 
urine among patients that have urine PB/PCs. Other mechanisms may be involved in 
non-CD19hi patients, since IFNα/β and pDCs are not present in the urine, and urine T 
cells are predominantly CD8. CD19hi patients that have urine PB/PCs are more likely to 
develop Class III or IV proliferative nephritis, develop significant loss of kidney function, 
and progress to ESRD. This could be due to the production of autoAbs in the kidney 
and/or the production of IFNα/β and other pro-inflammatory cytokines by kidney resident 
pDCs. This scenario predicts that the presence of urine lymphocytes in non-LN patients 
identifies patients likely to develop nephritis, and those CD19hi patients that have urine 
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PB/PCs, pDCs, a high CD4:CD8 ratio and high IFNα/β levels are likely to develop 
severe LN and progress to ESRD.  
In summary, we find in a cross sectional analysis of SLE patients that B cells, T 
cells, and pDCs are present in urine. Differences between patients in these cells and in 
IFNα/β in conjunction with the presence or absence of an expanded CD19hi population 
in peripheral blood correlate with the class of LN, active disease, and progression to 
CKD and ESRD. We propose that these cells and IFNα/β in the urine are of kidney 
origin and that their presence in urine reflects the immunopathology of the kidney. Thus, 
analysis of urine to identify immune cells and cytokines may provide insight into the 
immunopathological events that occur in the kidney. Importantly, such an analysis may 
identify patients likely to develop LN and progress to ESRD, and would be amenable to 
serial sampling to monitor disease progression and responsiveness to therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 58
 
Table 2.1:  Demographics of SLE patients, normal controls, and disease controls  
   SLE Patients  Normal controls      ANCA Disease Control 
       (n = 69)        (n = 20)      (n = 5) 
 
Age, years         41.2           37.3        40.3 
Ethnicity 
     Caucasian        30 %           25.0%              40.0% 
     Hispanic                     4.0%                        5.0%          0.0%  
     African American       62.1%           50.0%         40.0%  
     American Indian          1.4%           5.0%                 0.0%  
     Others            2.7%                 20.0%         20.0%  
Sex  
     Female                        92%           90.0%                              60.0% 
     Male                              8%           10.0%                             40.0% 
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Table 2.2 Number and percentage of SLE patients with B cells or T cells in urine 
Urine lymphocytes      Number and percentage of  
                          patient (N=69)               
 
B cellsa             44 (64%) 
T cells with or              55 (80%) 
without B cells 
 
aB cells were always present with T cells in patient urine.
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Table 2.3: The number and percentage of non-LN and LN patients with or without 
urine lymphocytes
 
      Lymphocytes present   Non-LN              LN          
         in urine                         (N=28)                      (N=41) 
 
        B cells and/or T cells                        17 (61%)                    38 (93%)   
      No B cells or T cells              11 (39%)                      3   (7%)           
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Table 2.4:  Summary of clinical therapy of patients analyzed  
Therapeutic regimena       MM          Predb      AZA      CYTO    HC     Ritux  
                             (N=39)    (N=69)    (N=10)    (N=2)  (N=10) (N=4)                                                      
Urine B cell phenotype 
Naïve/memory                      10            21           4   1     4       4 
  
PB/PCs               17            18           3            1           4       0 
 
None                          12            30           3            0           2           0 
 
aMedications that each Pt was taking at the time of blood draw.    
bAzathioprine (AZA), Hydroxychloroquine (HC), Mycophenolate mofetil (MM) prednisone 
(Pred), Rituximab (Ritux), Cytozan (Cyto) 
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 Table 2.5:  Number and percentage of non-CD19hi and CD19hi patients with urine 
naïve/memory B cells or PB/PCs. 
 
Urine Phenotype   Non-CD19hi Patients     CD19hi Patients    p valuea 
                                (N=30)                        (N=39) 
 
Naïve/memory B cells             10 (33%)               14 (36%)  ns 
          PB/PC                          7 (23%)               14 (36%)  ns 
           None              13 (43%)               11 (28%)  ns
 
aFishers exact test  
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 Table 2.6:  The number and percentage of non-LN and LN patients with urine 
naïve/memory or PB/PCs. 
 
Urine B cell phenotype     Non-LN  LN/CKD/ESRD       p valuesa 
                      (N=28)                (N=41)           
 
Naïve/memory   12(43%)           11(27%)                  ns 
     B cells  
 
PB/PC     2(7%)              19(46%)           0.0016 
 
None             14(50%)             11(27%)              ns 
 
aFishers exact test
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Table 2.7:  The number and percentage of non-proliferative LN, proliferative LN, 
and CKD/ESRD patients with no B cells, naïve/memory B cells, or PB/PC in their 
urine. 
 
 
Urine B cell   Non-Proliferative LN    Proliferative LN             p valuea 
 Phenotype              (Class I,II,V)                 (Class III,IV ±V) 
                   (N=18)                             (N=23)                   
Naïve/memory          7 (39%)                  4 (17%)                      ns          
      B cells 
 
      PB/PC                     2 (11%)       17 (74%)                <0.0001         
 
       None           9 (50%)                   2 (9%)                    0.0046      
 
aFishers exact test 
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Table 2.8:  SLE urine B cell phenotype and disease activity (SLEDAI scores) 
 Inactivea Active p value 
Naïve/memory 18 3 NS 
PB/PC 6 12 0.0153 
None 27 3 NS 
    
Non-Lupus nephritis 25 3 0.0244 
Lupus nephritis 26 15 
 
 
Non-CD19hi 25 5  
CD19hi 26 13  
 
aInactive disease is defined 
as a SLEDAI score <8; active 
disease is a score > 8.  
   
 
aFishers exact test 
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Figure 2.1:  FACS analysis of urine lymphocytes in SLE patients  
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Figure 2.2 SLE patients segregate into two subsets based on urine B cell phenotype 
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Figure 2.3 Urine B cells are likely of kidney origin     
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 Figure 2.4: Urine PB/PCs correlate with severity of LN 
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Figure 2.5 Higher levels of IFNα/β and higher frequencies of pDCs correlate with the 
presence of PB/PCs in urine of SLE patients  
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Figure 2.6 A high CD4:CD8 ratio and increased DN T cell numbers is associated with 
LN, urine PB/PCs, and disease activity  
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 S2.1 Frequency of IgG+ cells in urine  
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S2.2 Higher levels of IFNα/β and higher frequencies of pDCs are associated with urine 
PB/PCs 
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S2.3 FACS analysis of urine lymphocytes in SLE patients 
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S2.4 FACS analysis of DN T cells in the urine of SLE patients 
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Figure Legends 
 
Figure 2.1. FACS analysis of urine lymphocytes in SLE patients (A) Immune cells were 
isolated from urine of SLE patients and stained for CD19, CD3, CD4 and CD8, and 
analyzed by FACS. The gating scheme is shown in the representative histograms. The 
gate in the first histogram shows total lymphocytes based on forward scatter (FSC) and 
side scatter (SSC) properties.  Each gate in the bottom histogram distinguishes the 
different lymphocyte population present in urine. CD3+ T cells are further separated into 
CD4+, CD8+ and DN T cells in the top histogram.  (B) A higher percentage of T cells are 
present in the urine, and among T cells, CD8 T cells are present at a higher frequency 
than CD4 and DN T cells.  Percentages of B and T cells were calculated based on the 
total lymphocyte gate as shown in the first histogram (Fig. 1A).  
Figure 2.2. SLE patients segregate into two subsets based on urine B cell phenotype.  
(A-C) FACS analysis of peripheral blood and urine B cells from SLE patients. (A and B) 
Representative histograms that show the phenotype of urine B cells are similar to the 
phenotype of peripheral blood B cells. Urine immune cells were stained for CD19, 
CD20, CD21, CD27, CD38, IgD, IgG, and IgM and analyzed by FACS. (C) The graph 
shows the frequency of peripheral blood CD19hi B cells correlates significantly with the 
frequency of urine CD19hi B cells (p=0.0069,  r2=0.3258). Each data point represents an 
individual patient. (D and E) In addition to having urine naïve/memory B cells, we find 
that urine B cells have a PB/PC phenotype in 21 of 44 patients. (F) PBMC and urine 
immune cells from 3 SLE patients with urine PB/PCs and 3 patients with urine 
naïve/memory B cells were used in an ELISpot assay for IgG. 105 PBMCs were 
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collected from each patient and plated as positive controls. The graph shows IgG ASCs 
per 10 ml of urine.  
Figure 2.3.  Urine B cells are likely of kidney origin.  (A) Representative histograms 
show the frequency of CD19+ B cells in the blood of HD and blood and urine of an SLE 
patient treated with Rituximab. (B) The graph represents four patients that were treated 
with Rituximab six to nine months prior to analysis. B cells were undetectable in 
peripheral blood, but present in the urine of all four patients.      
Figure 2.4.  Urine PB/PCs correlate with severity of LN.  (A) eGFR was calculated as 
described in materials and methods and graphed for comparison LN and non-LN 
patients (A), CD19hi and non-CD19hi patients (B), and patients with naïve/memory B 
cells, PB/PCs, and no B cell in their urine (C). (N=16;  * p<0.05,  ** p<0.01, ***p<0.001)      
Figure 2.5. Higher levels of IFNα/β and higher frequencies of pDCs correlate with the 
presence of PB/PCs in urine of SLE patients. Plasma and urine was collected from HD, 
ANCA and SLE patients and cultured with WISH cells to determine IFNα/β activity as 
described in Materials and Methods. (A) IFIT1 expression by WISH cells is shown for 
plasma and urine from patients with either naïve/memory B cells or PB/PCs in their 
urine. Negative control is expression by WISH cells in the absence of plasma or urine, 
and the positive control is the addition of recombinant IFNα to WISH cells. (B)  IFIT1 
expression by WISH cells is shown for plasma and urine of HD in comparison to CD19hi, 
non-CD19hi, and ANCA patients. (C) Regression plot of IFIT1 expression in plasma and 
serum showing a negative correlation. Each point represents and individual patient. (N= 
23) (D)  PBMCs and urine of HD and urine cells from SLE patients were stained for 
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blood dendritic cell antigen- 2 (BDCA2), CD19 and CD21 and analyzed by FACS. 
Representative histograms are shown for a HD and SLE patient. (E) The percentage of 
pDCs among PBMC and urine cells is shown for SLE patients with urine naïve/memory 
B cells and urine PB/PCs. (F) The percentage of pDCs among PBMC and urine cells for 
HD and CD19hi and non-CD19hi patients is shown. (G) Regression plot of IFIT1 
expression and the percentage of pDCs showing a positive correlation. Each point 
represents an individual patient. (N=13)  (H) The fold change in IFIT1 expression 
induced by non-LN (NLN) and LN patient plasma and urine over that for HD plasma and 
urine. (I) The percentage of pDCs among PBMCs and urine cells in HD and non-LN and 
LN SLE patients. (*p<0.05, ** p<0.01, ***p<0.001) 
Figure 2.6. A high CD4:CD8 ratio and increased DN T cell numbers is associated with 
LN, urine PB/PCs, and disease activity. Immune cells were isolated from urine of HD, 
ANCA, and SLE patients and stained for CD3, CD4 and CD8 and analyzed by FACS. 
(A-C) The CD4:CD8 ratio is shown for the PBMCs and urine cells from the indicated 
patient populations and controls. In B, the ratio is shown for patients with urine 
naïve/memory B cells, urine PB/PCs and no urine B cells. (D) A regression plot of the 
urine CD4:CD8 ratio versus disease activity as measured by SLEDAI shows a positive 
correlation. Each point represents an individual patient. (E-G) The number of DN T 
cells/50 ml of urine is shown for the indicated patient populations and controls. (H) A 
regression plot of the urine DN T cell number versus SLEDAI shows a positive 
correlation. Each point represents and individual patient. (* p<0.05,** p<0.01, 
***p<0.001). 
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Supplemental Figure 2.1: Frequency of IgG+ cells in urine. Immune cells were isolated 
from blood of HD and blood and urine of SLE patients and stained for CD19 and IgG 
and analyzed by FACS. The graph shows the frequency of IgG+ cells in blood and urine 
of SLE patients. Each point represents an individual patient.    
Supplemental Figure 2.2: Higher levels of IFNα/β and higher frequencies of pDCs are 
associated with urine PB/PCs. (A-C and E) Plasma and urine was collected from HC, 
ANCA and SLE patients and cultured with WISH cells to determine MX1 and PKR gene 
expression as proxies for IFNα. Shown are the levels of gene expression for the 
indicated patient and control populations. The negative control is gene expression by 
WISH cells in the absence of plasma or urine and the positive control is added rIFNα. (* 
p<0.05, **p<0.01). Regression plot of MX1 expression (D) and PKR expression (F) 
induced in WISH cells by patient urine and plasma (N=10). Each point represents an 
individual patient.  
Supplement Figure 2.3: FACS analysis of urine lymphocytes in SLE patients. (A-I) 
CD3, CD4, CD8, and DN T cells from blood and urine were enumerated by FACS. (A-C) 
Frequency of T cells (CD3+, CD4+, or CD8+) in the blood and urine of the indicated 
patient and control  populations. (D-F) Frequency of T cells (CD3+, CD4+, or CD8+) in 
the blood and urine of HD and SLE patients with urine naïve/memory B cells, urine 
PB/PCs, or no urine B cells is shown. (G-I).  Frequency of T cells (CD3+, CD4+, or 
CD8+) in the blood and urine of the indicated control and patient populations. (J-L) The 
number of CD4+ T cells and (M-O) CD8+ T cells per 50 mls of urine in the indicated 
control and patient populations.  Each point represents an individual patient. (N=22  * 
p<0.05,  ** p<0.01, ***p<0.001). 
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Supplemental Figure 2.4: FACS analysis of DN T cells in the urine of SLE patients.  
PBMC and urine cells were stained for CD3, CD4 and CD8 and analyzed by FACS. (A-
C) The percentage of DN T cells among PBMCs and in urine of the indicated control 
and patient populations is graphed (N=22).  *p<0.05, **p<0.01, ***p<0.001) 
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Chapter 3:  Activated CD19hi B cells and Foxp3lo Non-Suppressive T cells 
correlate with progressive lupus Nephritis 
    
3.1. Introduction 
 Systemic lupus erythematosus (SLE) is characterized by the production of 
autoantibodies (autoAbs) that drive immune-complex related inflammation in various 
tissues and organs (Tsokos GC. 2011) (Mak A. 2014).   The etiology is unknown, but 
has both genetic and environmental components. The development of lupus nephritis 
(LN) is a principal cause of morbidity and mortality in SLE, but the underlying 
immunopathological mechanisms of LN are still largely unknown. One of the major 
mechanisms that result in the production of autoAbs by B cells and plasma cells (PCs) 
leading to LN, is the breakdown of immune tolerance.   Recent evidence suggests that 
T cells enhance the production of autoAbs by giving help to B cells, stimulating them to 
differentiate, proliferate, and mature (Mak A. 2014) (Shlomchik MJ. 2001) .  Thus, both 
autoreactive B cells and T cells are central contributors to the development and 
progression of SLE.  
T cells play a major role in SLE (Shlomchik MJ. 2001, Apostolidis SA. 2011) and 
are present in kidney and urine of LN patients (Dolff S. 2010, Enghard P 2012, Dolff S. 
2013, Sun  C-Y. 2013, Kinloch  AJ. 2014) (Enghard P. 2014).  Autoreactive T cells 
enhance the production of autoAbs by B cells.  Chan et al found that B cells that are 
capable of expressing Ab, but impaired in Ab secretion, still result in mice developing 
nephritis (Chan OT. 1999).  This suggests that B cells may act as antigen presenting 
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cells in order to activate T cells.   Previous research on SLE kidney biopsies show that 
Tfh cells are present and in close contact with B cells (Liarski VM. 2014), suggesting a 
possible interaction between the two cell types in tissue.  In addition to providing B cell 
help, T cells are also major producers of proinflammatory cytokines, and this may also 
contribute to LN development. 
The distribution of different T cell subsets is abnormal in SLE, with an increase in 
the pro-inflammatory Th17 cell population and a decrease in the anti-inflammatory T 
regulatory (Tregs) cell population (Crispín JC. 2008), (Moulton VR. 2011).   Th17 cells 
are an important subset of CD4 T cells.  This subset is characterized by the production 
of IL-17, a proinflammatory cytokine, and is shown to play a vital role in SLE (Crispín 
JC. 2008, Korn T. 2009).  Serum levels of IL-17 were found to correlate with the SLE 
disease activity score, SLEDAI-2K (Crispín JC. 2008), suggesting IL-17 as a major 
contributor to disease pathology.  
In addition to IL-17, the Th1 pro-inflammatory cytokine, IFN-gamma (IFN-γ) has 
recently been implicated in disease pathogenesis (Shovman O. 2006, Davis LS. 2011).  
Both innate and adaptive immune cells generate IFN-γ and enhanced levels of IFN-γ 
have been recently reported in some SLE patients.  A recent study by Coquery et al 
suggested a unique mechanism by which IFN-γ may contribute to SLE pathogenesis by 
inducing BAFF production by neutrophils (Coquery CM. 2014).  LN patients show a 
predominant Th1 phenotype with high IFN-γ expression in peripheral blood and 
glomerular that parallels the severity of renal damage (Tucci M. 2008).  As well as, the 
serum levels of C3, C4 and anti-dsDNA Abs exhibit a significantly positive correlation 
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with glomerular expression of IFN-γ (Su DL. 2012).  Thus, IFN-γ may be a key cytokine 
in disease pathogenesis.  
 Distinct T cell subsets associate with SLE.  Recent observation of human 
peripheral blood T cells by Miyara et al found several different subsets that are 
characterized by the expression of Foxp3, a Treg specific transcription factor (Miyara M. 
2009). The three subsets are CD4+CD45RA+Foxp3lo (Fr I) resting Treg cells, 
CD4+CD45RA-Foxp3hi (Fr II) activated Treg cells, both of which are highly suppressive 
in vitro, and cytokine-secreting non-suppressive CD4+CD45RA-Foxp3lo  (Fr III) non-
suppressive cells (Miyara M. 2009). In SLE, the frequency of Fr III non-Treg cells is 
increased compared to healthy donor.  More interesting is that Fr III did not show 
regulatory capabilities and this subset is enriched in IL-17 and IFN-γ producing cells 
(Miyara M. 2009).  Their model suggests that IL-17 and IFN-γ enriched Fraction III T cell 
subsets, contributes to disease pathogenesis.   
CD19hi B cells are a distinct B cell population that associates with the 
progression to ESRD and other neurological complications (Culton DA. 2007, Nicholas 
M. 2008).    The presence of an expanded CD19hi B cell population correlates with high 
titers of certain autoAbs, including anti-Sm, a hallmark anti-ribonucleoprotein (RNP) 
autoAb of SLE (Nicholas M. 2008). Interestingly, the circulating anti-Sm B cells are 
CD19hi B cells and the anti-Sm titer correlates with the frequency of CD19hi B cells 
specific for Sm (Nicholas M. 2008). These data suggest that CD19hi B cells contribute to 
disease, and therefore, understanding the function of CD19hi B cells may provide insight 
into disease mechanisms. 
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We report here a significant correlation between the frequency of CD19hi B cells 
and the frequency of CD45RA-Foxp3lo (Fraction III) non-suppressive T cells. This 
population is expanded in CD19hi patients and the frequency of IL-17 and IFN-γ 
producing cells are also higher in CD19hi patients.   Patients with both an expanded 
frequency of CD19hi B cells and Foxp3lo T cells were more likely to have LN.  These 
data suggest a possible interaction between CD19hi B cells and Foxp3lo T cells that may 
contribute to SLE and the development of LN.  Therefore, understanding the function of 
CD19hi B cells and Foxp3lo T cells may provide insight into disease mechanism. 
3.2. Materials and Methods 
3.2.1 Healthy donor and patient peripheral blood and urine samples. 
 Peripheral blood samples were collected from 10 healthy donors (mean age: 
37.3 years, range: 28-58, gender 16 females, 4 males) and 30 patients (mean age 41.2 
years, range 22-77, gender 62 females, 7 males) with SLE; in some cases, the same 
healthy control or patient was used on multiple occasions or in multiple experiments. 
Patients were included in this study after informed consent in accordance with our 
institutional internal review board, and fulfilled at least four of the established American 
College of Rheumatology 1997 revised criteria for SLE. Samples were gathered during 
routine clinic visits.   
Peripheral blood samples were collected into Vacutainer CPT tubes with sodium 
heparin (BD Biosciences) and sera and peripheral blood mononuclear cells (PBMCs) 
isolated per the manufacturer’s protocol. PBMCs were washed once with sterile 
phosphate buffered saline (PBS) before continuing with any protocol.   
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 3.2.2 Cell surface staining and FACS analysis 
  For surface staining, cells were prepared as described above and stained on ice 
for 20 min and then washed twice with 1X PBS.  The antibodies (Abs) used were as 
followed: anti-CD19APC, anti-CD19PAC BL, anti-CD19 PE-CY7, anti-CD20 APC-CY7, 
anti-CD4 Pac Blue, anti-FOXP3 Alexa 647, anti-CD127 PE, anti-IFN-y PE, anti-IL-PE 
(Biolegend, San Diego CA).  To distinguish live cells, Pacific Orange was added at a 
concentration of 0.02 mg/ml to each sample and incubated at room temperature for 20 
min, after which each sample was washed three times with FACS buffer. 
3.3 Results 
3.3.1 SLE patients with an expanded CD19hi B cell population have a higher 
frequency of CD45RA-Foxp3lo T cells.  
 Several reports indicate significant T cell abnormalities in SLE. In a recent report 
by Miyara et al., they show an expanded CD45RA-Foxp3lo non-suppressive T cell 
subset in the peripheral blood of SLE patients.  We postulated that patients with an 
expanded CD45RA-Foxp3lo T cell subset have an expanded CD19hi B cell 
subpopulation. We collected blood from 10 healthy controls (HC) and 30 SLE patients. 
This lupus patient cohort averaged 39.2 years of age and was 95% female and 72% 
African American (Table 3.1).  Peripheral blood from patients were Ficoll-purified to 
obtain PBMCs and stained for specific B and T cell surface markers 
CD19,CD21,CD4,CD127, CD45RA, CD25 and intracellular staining for Foxp3, IL-17 
and IFN-γ.  
Figure 3.1A displayed histograms representing the plotting strategy based on 
published data by Miyara et al.   Each gate delineates a specific CD4+ T cell subset with 
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the present and/or absence of CD45RA and Foxp3 expression identifying unique T cell 
Fractions (Fr). Consistent with previous reports, we found SLE patients had a lower 
frequency of Fr I and II compared to HC (Figure 3.1B). In contrast SLE patients had a 
significantly higher frequency of Fr III (Figure 3.1B).  
Further analysis revealed that CD19hi patients had an increased frequency of Fr 
III T cells (Figure 3.1B). We found non-CD19hi patients had a lower percentage of T 
cells in Fr I and III (Figure 3.1B). Interesting, the frequency of T cells in Fr III significantly 
correlated with the frequency of CD19hi B cells (Figure 3.1C) suggesting a possible 
interaction between the Foxp3lo T cells and CD19hi B cells.  We also found LN patients 
had a higher frequency of Fr III compared to non-LN patients (Figure 3.1B) and a lower 
frequency of Fr II.  
3.3.2 Fraction III is enriched in proinflammatory cytokines 
 IL-17 and IFN-γ pro-inflammatory cytokines have been implicated as a 
contributor to SLE pathogenesis (Apostolidis SA. 2011).  Fr III is enriched in both IL-17 
and IFN-γ and the frequency of this Fr is increased in CD19hi patients.  To determine 
whether CD19hi patients have an increased frequency of IL-17 and IFN-γ producing 
cells, PBMC were collected from HC, CD19hi and non-CD19hi SLE patients and cultured 
with PMA/Ionomycin for 5 hrs. Cells were then stained for surface and intracellular 
proteins with specific T cell Abs for analysis via FACS.  Representative dot plots show 
the presence of CD4+IL17+ T cells in Fr II and III (Figure 3.2A) and CD4+IFN-γ+ cells in 
Fr III (Figure 3.2B).     Consistent with previous reports, the frequency of IL-17 and IFN-
γ producing cells were significantly higher in Fr III compared to Fr I and II (Figures 3.2C 
and 3.2F). Both CD19hi and LN patients had a higher frequency of IL-17 and IFN-γ 
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producing cells in peripheral blood (Figure 3.2D, 3.2E, 3.2G and 3.2H) suggesting that 
Fr III contributes to the overall IL-17 and IFN-γ pool in both CD19hi and LN patients. 
3.3.3 IL-17 and IFN-γ enriched Fract III T cell subset associate with disease 
activity and proliferative nephritis. 
 A higher frequency of IL-17 and IFN-γ producing cells are present in the 
peripheral blood of LN patients compared to non-LN.  This is consistent with reports that 
IL-17 proteins are elevated in LN patients and IL-17 can be identified in kidney biopsies 
(Crispín JC. 2008).  The frequency of Fr III is significantly higher in LN patients.   LN is 
categorized by class (class 1-5).  Patients with class III/IV or in combination with V 
(proliferative LN) are more likely to progress to chronic kidney disease and ESRD.  To 
determine whether there are differences in the frequency of Fr III between patients with 
proliferative LN and non-proliferative LN, we analyzed the percentage of each Fr 
between each subgroup.   The frequency of Fr I and II were both lower in LN classes 
regardless of having proliferative or non-proliferative LN (Figure 3.3A and 3.3B) and 
there was not a significant difference between the frequency of Fr III between the two 
subgroups (Figure 3.3C).   Interestingly, patients with proliferative LN had a higher 
frequency of both IL-17 and IFN-γ producing cells in peripheral blood (Figure 3.3D and 
3.3E) suggesting a role for both cytokines in the development of proliferative nephritis.   
Overall, we report a significant correlation between the frequency of CD19hi B 
cells and the frequency of Foxp3lo non-suppressive T cells.  This fraction of T cells is 
enriched in IL-17 and IFN-γ producing cells. Importantly, our data shows an association 
between the frequencies of IL-17 and IFN-γ producing cells and LN class. Further 
research is required to determine the significant of these findings. 
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3.4. Discussion 
 CD19hi B cells are recently activated memory B cells (MBCs), and where 
differentiation into antibody secreting cells (ASC) occurs is unknown.  A possible site of 
differentiation is the kidney.  In this environment we proposed that CD19hi B cells are 
central mediators that may influence several immune cell abnormalities.  Miyara et al. 
found some SLE patients have an expanded CD45RA-Foxp3lo (Fr III) non-suppressing T 
cell population that is enriched in IL-17 and IFN-γ producing cells (Miyara M. 2009). We 
also find a higher frequency of Fr III T cells in the peripheral blood of our cohort of SLE 
patients. CD19hi patients have a higher frequency of Fr III T cells compared to non-
CD19hi and the percentage of CD19hi B cells significantly correlate with the percentage 
of Fr III T cells suggesting a possible interaction between the two subsets. One 
particularly interesting possibility is that CD19hi B cells present antigen to Foxp3lo T cells 
inducing clonal expansion, or CD19hi B cells are directly involved in the transition of 
Tregs to Foxp3lo non-suppressive T cells.  The ability of B cells to act as antigen 
presenting cells in autoimmune disease was demonstrated in autoimmune-prone mice 
that had an induced genetic lesion such that their B cells did not secrete 
immunoglobulin.  These mice showed T cell activation and develop nephritis (Kurts C. 
2007).  Having a CD19hi B cell or Fr III T cells alone does not directly correlate with LN; 
however, having both an expanded CD19hi B cell subset and an expanded Fr III T cell 
subset together significantly associate with LN (data not shown) and this suggests that 
both subtypes are involved in renal pathology. CD19hi B cells are present in urine of LN 
patients (Scott E 2015, paper in review) suggesting that they are present in kidneys but 
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whether Fr III T cells are present remains to be determined.  Our model suggests a 
direct interaction between the two cell subtypes that may result in nephritis.    
It is also possible that CD19hi B cells and Foxp3lo T cells do not interact and that 
an unknown factor (secreted cytokine, cell or antigen) independently drives the 
expansion of both populations.  IL-6 is a pleiotropic proinflammatory cytokine. B cells 
stimulated by CpG and anti-CD40 produced large amounts of IL-6 (Wagner M. 2004).  
Lampropoulou and colleagues (Lampropoulou V. 2008) reported that B cells secrete 
large amounts of IL-6 in response to polyclonal activating stimuli and subsequently T 
cell proliferation in vitro (Lampropoulou V. 2008).   Barr reports that the production of IL-
6 by B cells had a direct effect on CD4+ T cell differentiating into Th17 cells (Barr TA. 
2012).   CD19hi patients have higher levels of IL-6 in plasma (unpublished data) but 
whether CD19hi B cells are the major producers of IL-6 remains to be determined.  
Thus, we suggest two possible mechanisms for the expansion of Foxp3lo T cells.  One 
mechanism includes B cells directly as antigen presenting cells to modulate Foxp3 gene 
expression.  The other mechanism may include factors such as cytokine secretion 
produced by B cells or other immune cells that drive expansion of both CD19hi B cells 
and Foxp3lo T cells. 
SLE patients have an increased frequency of IL-17 and IFN-γ producing T cells 
in peripheral blood associated with higher levels of IL-17 and IFN-γ in the sera of SLE 
patients. More interesting is we find a higher frequency of IL-17 and IFN-γ producing 
cells present in the peripheral blood of CD19hi patients compared to non-CD19hi 
patients. As stated above, Fr III is enriched in IL-17 and IFN-γ producing T cells (Miyara 
M. 2009).  However, several other T cell populations are enriched in IL-17 producing 
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cells including double negative T cell subsets in humans. Whether Fr III is responsible 
for the higher levels of IL-17 and IFN-γ in LN is interesting and whether this population 
alone, contributes to proliferative LN will be important to understand the mechanism that 
results in a more aggressive disease.    
In conclusion, we suggest CD19hi B cells are recently activated autoreactive B 
cells that migrate to sites of inflammation and contribute to disease pathogenesis.  In 
addition to the production of autoAbs and cytokines, B cells can activate autoreactive T 
cells.  We found a significant correlation between CD19hi B cells and CD45RA-Foxp3lo T 
cells suggesting a possible interaction between the two subsets.  Further analyses of 
these two subsets are required to determine the mechanism involved.   
 91
 
 
Figure 3.1.  CD19hi B cells correlate with an expanded Foxp3lo T cell subset in SLE. An 
environment rich in apoptotic debris may activate CD19hi B cells resulting in the 
production of autoAb (IgG anti-RNP).  Anti-RNP ICs along with direct contact of CD19hi 
B cells with pDCs may enhance the pDCs ability to produce IFNα. mDCs along with 
CD19hi B cells present antigen to Foxp3lo T cells resulting in the production of IL-17.    
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Table 3.1:  Demographics of SLE patients, normal controls, and disease controls 
   SLE Patients    Healthy controls (HC)       
       (n = 30)                    (n = 10)       
 
Age, years         39.2                        37.3         
Ethnicity 
     Caucasian        30 %                                   25.0%               
     Hispanic                     4.0%                                                 5.0%     
     African American       72.1%                                  50.0%           
     American Indian          1.4%                                    5.0%           
     Others            2.7%                                        20.0%           
Sex  
     Female                        95%                                 90.0%                               
     Male                              8%                                10.0%                              
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Figure 3.1 SLE patients with an expanded CD19hi B cell population have a higher 
frequency of CD45RA-Foxp3lo T cells 
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Figure 3.2 Fraction III is enriched in proinflammatory cytokines  
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Figure 3.3 Fraction III associate with proliferative nephritis 
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Figure Legends 
 
Figure 3.1. SLE patients with an expanded CD19hi B cell population have a higher 
frequency of CD45RA-Foxp3lo T cells. (A) Immune cells were isolated from PBMCs of 
SLE patients and stained for CD19, CD3, CD4, CD25, CD45RA, and Foxp3 and 
analyzed by FACS. The gating scheme is shown in the representative histograms. The 
gate in the first histogram shows CD4+ T cells within each fraction based on the level of 
Foxp3 on the X axis and CD45RA on the Y axis.  (B) The percentages of T cells in each 
fraction were calculated based on the gating scheme as shown in the first histogram 
(Fig. 3.1A). (C)The graph shows the frequency of peripheral blood CD19hi B cells 
correlates significantly with the frequency of Fr III Foxp3lo T cells (p<0.0001,  
r2=0.5868). 
Figure 3.2. Fraction III is enriched in proinflammatory cytokines.  (A-B)  Immune cells 
were isolated from PBMCs of SLE patients and stained for CD19, CD3, CD4, CD25, 
CD45RA, Foxp3, IL-17 and IFN- y and analyzed by FACS. The gating scheme is shown 
in the representative histograms. The top dot plots represent unstimulated CD3+ CD4+ T 
cells from each fraction (Fraction I-III) and the bottom dot plots represent CD3+ CD4+ T 
cells from each fraction (Fraction I-III) stimulated with PMA/Ionomycin for 5 hrs.  The 
graphs show the frequency of IL-17+ cells (C-E) and IFN-y+ cells (F-H) in blood of SLE 
patients. Each point represents an individual patient (* p<0.05,  ** p<0.01, ***p<0.001).   
 Figure 3.3.  Fraction III associate with proliferative nephritis.  (A-E) Immune cells were 
isolated from blood of HC and SLE patients and stained for CD4, CD25, CD45RA, 
CD127, IL-17, and IFN-y and analyzed by FACS. The graphs show the frequency of Fr 
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I-III (A-C) and the frequency of IL-17+ cells and IFN- y (D-E) between the different LN 
classes. Each point represents an individual patient (* p<0.05,  ** p<0.01, ***p<0.001).   
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Chapter 4 Discussion 
 
4.1  Implications for the Progression of SLE 
 Systemic lupus erythematosus (SLE) is a chronic autoimmune disease 
characterized by the production of autoantibodies to intracellular proteins and nucleic 
acids.  B cells play a central role in disease pathogenesis.  In addition to autoantibody 
(autoAb) production, B cells produce cytokines and act as antigen presenting cells 
(APCs) to stimulate autoreactive T cells. Several B cell abnormalities exist in SLE 
patients but these abnormalities are not attributable to a single subset of B cells, and, 
therefore they do not identify autoreactive B cells.  The inability to distinguish 
autoreactive from non-autoreactive B cells impedes our understanding of the molecular 
mechanisms that results in the loss of tolerance in human SLE.  
 Previously, our lab identified an expanded B cell population in peripheral blood 
of SLE patients that is enriched in autoreactive B cells (Culton DA. 2007, Nicholas M. 
2008), which in turn express high levels of CD19 and CD20 and low levels of CD21. 
This CD19hi B cell subset comprises 1-3% of peripheral blood B cells in healthy 
individuals, but up to 20% in some SLE patients (Culton DA. 2007, Nicholas M. 2008). 
CD19hi B cells exhibit a memory B cell phenotype, are somatically mutated, produce 
predominantly IgG, and are enriched in Sm specificity, a hallmark of SLE (Culton DA. 
2007, Nicholas M. 2008). Notably, patients with an expanded CD19hi population (CD19hi 
patients) have different serum autoAbs (including anti-Sm) compared to patients lacking 
the expanded CD19hi pool (non-CD19hi patients). Furthermore, the expanded CD19hi 
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population appears to be stable over time and correlates with end stage renal disease 
(ESRD) and neurological complications. Thus, we propose that CD19hi and non-CD19hi 
patients differ in the underlying mechanisms of disease. We hypothesize that CD19hi B 
cells are recently activated autoreactive B cells that are migrating to sites of 
inflammation, clonally expanding, differentiating into plasma cells and contributing to 
disease via autoantibody production and antigen presentation.   
CD19 overexpression may result in the loss of B cell tolerance.  On the surface 
of B cells, CD19 functions as a co-receptor for the BCR.  CD19 interacts with CD81, 
Leu13, and CD21, forming the BCR complex (Knoetig SM. 2002).  The intracellular 
domain of CD19 is involved in intracellular signaling cascades, primarily but not 
exclusively regulating signals downstream of the BCR (Knoetig SM. 2002).  The 
biological relevance of high expression of CD19 on B cells is not clear. In murine 
models, CD19 deficient mice show impaired B cell responses. However, over 
expression of CD19 in mice results in hyperresponsive B cells and the production of 
autoantibodies (Inaoki M. 1997, Saito E. 2002).  Thus CD19 is a regulator of BCR 
signaling threshold, and is implicated in the control of peripheral tolerance. 
The properties of CD19hi B cells suggest that these cells are recent immigrants 
from germinal centers (GC). CD19hi B cells express several activation markers that are 
up-regulated during GC processes.  One interesting finding was the identification of two 
distinct subsets characterized by the expression of CD95 (CD19hi95+ and CD19hi95-). 
We propose that both subsets are products of GC; however, CD19hi/95- B cells may be 
pre-programmed to remain memory cells and CD19hi/95+ B cells are transitioning into 
plasmablasts (PBs).  Transcription factors such as PAX-5 and Bcl-6 are down-regulated 
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and XBP-1, IRF-4 and BLIMP1 up-regulated on pre-PBs.   CD19hi/95+ B cells express 
lower PAX-5 and Bcl-6 and higher XBP1, IRF-4 and BLIMP-1 compared to CD19hi/95- B 
cells.  Another scenario is that CD19hi/95- B cells have down-regulated CD95 
expression to maintain a memory phenotype. Perhaps the entire subset expressed 
CD95 and upon antigen stimulation CD95 expression is lost. Finally, CD19hi/95+ B cells 
may be T independent (TI) memory B cells (MBCs).  
  CD19hi/95+ B cells are phenotypically similar to TI MBCs.  In the spleen, marginal 
zone (MZ) B cells are major contributors to an early TI response (Cyster JG. 2000, 
Martin F. 2001).  MZ B cells are considered to be more “hyperactive” compared to 
follicular (Fo) B cells in processing and presentation of antigen and stimulation of T cells 
(Gunn KE. 2006, Pillai S. 2009). TI responses are important in defending against blood-
borne infection that can lead to endotoxic shock.  Typically, MZ B cell responses are 
rapid and short lived as they rapidly develop into extra-follicular plasma cells that secret 
IgM within the first three days (Gunn KE. 2006).  Based on the surface phenotype of MZ 
B cells, it is plausible that CD19hi B cells which express high activation markers and 
have a pre-plasmablast phenotype, are TI MBCs.   
Peripheral blood CD19hi B cells do not secrete Ab.  Notably the correlation 
between the frequency of anti-Sm-specific B cells in the CD19hi population and anti-Sm 
titer suggests that CD19hi B cells are precursors to anti-Sm Ab secreting cells (ASCs). 
The site(s) at which CD19hi B cells differentiate into ASCs is not known. CD19hi B cells 
express high levels of CXCR3, a chemokine receptor that directs cells to sites of 
inflammation, and are responsive to the CXCR3 chemokines CXCL9 and CXCL10 
(Nicholas M. 2008).  Since patients with an expanded CD19hi population are more likely 
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to progress to ESRD, we reason that these cells migrate to the kidney to become ASCs.  
The contribution of immune cells to disease pathogenesis in the kidneys of lupus 
nephritis (LN) patients are poorly understood, in part due to constraints in serial 
sampling and analysis of biopsy tissue. With this in mind, we investigated whether 
CD19hi B cells are detected in patient urine and if so, whether a correlation with kidney 
pathology and function can be established.  Our analyses showed that, B cells, T cells, 
and pDCs are found in the urine of SLE patients. Over half of the patients analyzed 
contained urine B cells, and based on B cell phenotype, 2 patient groups of roughly 
equal size were defined; namely patients with naïve and memory B cells (including 
CD19hi B cells) versus PB/PCs-only. Interestingly, a strong correlation was seen 
between the frequency of peripheral blood and urine CD19hi B cells in SLE patients. It is 
unlikely, however, that urine PBs and plasma cells (PCs) are directly derived from 
peripheral blood, which contains only a very low frequency of PBs and PCs. Whether 
urine naïve/memory B cells are derived from peripheral blood or elsewhere along the 
genitourinary tract is less clear. It is significant, however, that urine but not peripheral 
blood naïve/memory B cells persist after rituximab therapy. Accordingly, we suggest 
that the kidney is the most likely source for both B cell populations. The presence of 
urine naïve/memory B cells in rituximab treated patients is particularly interesting since 
it indicates that kidney-resident B cells are not depleted by anti-B cell therapy. The latter 
observation is consistent with findings in mice and humans showing that certain B cell 
subsets are resistant to depletion. Kidney resident B cells likely include autoreactive B 
cells (Espeli M. 2011), which may subsequently expand and contribute to the clinical 
relapse seen following rituximab therapy. Finally, CD19hi B cells may promote tertiary 
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lymphogenesis in the kidneys.  Indeed, the kidney environment provides both T cell help 
to stimulate B cells and sufficient autoantigen to promote PC differentiation.  As well 
increased BAFF is present in the kidneys of some LN patients, promoting the survival of 
autoreactive B cells (de Zubiria Salgado A. 2012).  Thus local production of autoAbs 
may enhance the development of LN. 
CD19hi B cells are detectable in the urine of patients that have urine 
naïve/memory B cells. In contrast to our prediction of preferential migration to the kidney 
due to high CXCR3 expression and their association with severe kidney disease, the 
frequency of CD19hi B cells in urine is proportionate to that in peripheral blood. Thus, we 
have no evidence of preferential migration of CD19hi B cells to the kidney. However, it is 
notable that only CD19hi patients have urine PBs/PCs, raising the possibility that urine 
PBs/PCs derive from CD19hi B cells. This would explain the link between CD19hi 
patients and ESRD/CKD, since ESRD and CKD are only detected in patients with urine 
PBs/PCs. A comparison of the repertoires of peripheral blood CD19hi B cells and urine 
PBs/PCs may help clarify their relationship.  
IFNα secreted by pDCs is an important mediator of LN. Patients with high IFNα 
levels develop more severe LN, and a number of IFN-inducible genes are associated 
with SLE. Furthermore, patients receiving therapeutic IFNα develop an SLE-like 
disease. This association is strengthened by experiments in murine SLE where deletion 
of the IFNα receptor gene (ifnar) ameliorates disease in several models. Consistent with 
our previous findings that LN severity is increased in CD19hi patients, high plasma IFNα 
levels are also detected in CD19hi patients. IFNα may contribute to the formation or 
clonal expansion of CD19hi B cells, or alternatively, CD19hi B cells may contribute to 
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IFNα secretion by pDCs.  In regard to the latter, CD19hi patients have high levels of 
anti-RNP autoAbs, and anti-RNP ICs induce IFNα secretion by pDCs via TLR7 binding 
of RNA. Immune complex (IC) activation of pDCs through TLR7 is more potent at 
inducing IFNα secretion than TLR9 activation by ICs associated with DNA. Thus, the 
anti-RNP autoAbs preferentially produced by CD19hi B cells may account for the 
correlation between IFNα levels and CD19hi B cell frequency. IFNα production by pDCs 
in response to TLR7 activation requires B cell contact with pDCs, which could also 
contribute to this relationship between IFNα and CD19hi B cells.  
In two recent reports, urine CD4+ and CD8+ T cells were found to be associated 
with active disease  (Enghard P. 2012, Enghard P. 2014) (Dolff S. 2013).  In contrast, 
urine B cells have not been linked to active nephritis or proliferative nephritis.  In our 
study, an increased frequency and number of CD4 T cells in the urine correlated 
significantly with urine PB/PC in CD19hi patients with proliferative nephritis.  In contrast, 
the presence of naïve/memory B cells in urine associated with an increased frequency 
of CD8 T cells and non-proliferative nephritis. This suggests two distinct mechanisms 
where one involves a critical role for B cells in driving pathology. 
Based on these findings, we propose a model in which a progressive change in 
immune cells in the urine reflects kidney immunopathology during the development of 
LN and transition to CKD and ESRD. We propose that T cells are first to enter the urine 
and are present in nearly all patients including non-LN and LN patients. In non-LN 
patients, CD8 T cells predominate, but in LN patients CD4 T cells are largely found. B 
cells appear next in the urine, but only in patients with pre-existing urine T cells. This 
pool initially consists of naïve/memory B cells that persist in non-CD19hi patients. 
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However, in CD19hi patients naïve/memory B cells differentiate into PBs/PCs detected 
in the urine, due to increased IFNα levels produced by pDCs in the kidney. Both 
patients with urine naïve/memory and PBs/PCs may or may not have LN, and thus, the 
presence of either type in urine is not sufficient for LN. However, it influences the class 
of LN and the likelihood of progression to severe LN. Patients with naïve/memory B 
cells in urine are likely to develop non-proliferative LN (membranous) that fails to 
progress to CKD or ESRD, whereas CD19hi patients that switch to urine PB/PCs are 
likely to develop proliferative nephritis that progresses to CKD and ESRD.  
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Figure 4.1. A model of how immune cells in urine reflect renal immunopathology. 
CD4 and CD8 T cells are the first cell types to exit the kidney and appear in the urine of 
non-LN and LN patients.  A majority of T cells are CD8 in non-LN patients.  In contrast a 
majority of CD4 T cells and naïve/memory B cells are present in CD19hi/LN patients.  In 
CD19hi patients naïve/memory B cells differentiate into PBs/PCs detected in the urine 
and this is due to increased IFNα levels produced by pDCs in the kidneys.  PBs, pDCs 
T cells and IFNα can be detected in the urine of CD19hi patients with proliferative LN 
and these patients will likely progress to CKD and ESRD. B, B cells; T, T cells; PB, 
plasmablasts; pDCs plasmacytoid dendritic cells;IFNα, Interferon alpha. 
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4.2 Clinical Significance 
 Extensive longitudinal studies are required to better understand the role of B cell 
subsets before and during the progression of SLE. While our analyses were mostly 
cross sectional, some patients were in fact followed over a period of several years. 
Unfortunately, we did not observe any patient who initially had urine naïve/memory B 
cells who subsequently had a ‘switch’ to urine PB/PCs, as predicted by our model. This 
may be attributable to the long time frame for progression of human SLE and to 
treatment regimen. Alternatively, since CD19 over expression is found on activated, 
constitutively signaling B cells, the presence of these cells suggests unharnessed and 
aberrant B cell activation in patients. Consistent with this, we suggest that defining 
CD19hi versus non-CD19hi patients coupled with detection of urine pDCs and IFNα will 
identify LN patients with a high risk of CKD and ESRD. These patients would most likely 
benefit with aggressive therapy. Additional analysis of immune cells and cytokines may 
help in refining the progression of changes in the urine that are reflective of the kidney 
pathology. 
In most cases, SLE patients are prescribed similar inductive and maintenance 
therapies. The presence of an expanded CD19hi B cell subset in the peripheral blood or 
PBs/PCs in the urine will help identify patients that are at a greater risk to have more 
severe disease.  Treating only patients with high risk disease with aggressive 
immunosuppressive therapy may improve outcomes for patients.  For instance, not all 
SLE patients will benefit from and may in fact succumb to infections or organ 
dysfunction related to potent immunosuppressive drugs with severe side effects. 
Cellular biomarkers to predict disease outcomes may improve selection of appropriate 
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therapeutic options for the patients.  For example, non-CD19hi patients with LN 
associate with less severe nephritis (Class I and II) whereas CD19hi patients with LN 
develop aggressive proliferative nephritis (III, IV and in combination with V) that is more 
likely to progress to CKD/ESRD.  Future use of CD19hi B cells as a biomarker may help 
rheumatologists decide the best therapeutic options for their patients.   
The presence of immune cells in urine may provide a way to monitor kidney 
pathology and SLE progression.  Unlike kidney biopsies, collecting patient urine is non-
invasive and in most cases it is readily available.  Our data show that in addition to 
having an expanded CD19hi B cell subset, LN patients have distinct B cell subsets, T 
cells and pDCs along with high levels of IFNα in their urine, which associate with 
CKD/ESRD. Other cytokines and chemokines such as CXCL16, CX3CL1, TWEAK, IL-6 
and IL-10 are under investigation to identify additional biomarkers to more accurately 
delineate disease progression.   
4.3 Conclusion 
 Our long-term goal is to understand the molecular mechanisms that regulate 
autoreactive B cells and to use this information to develop targeted therapeutic 
approaches for the treatment of SLE.  The objective of this work was to identify 
autoreactive B cells that may infiltrate the kidneys of SLE patients and in turn drive 
disease pathology. We hypothesized that CD19hi B cells are recently activated 
autoreactive B cells that migrate to sites of inflammation, clonally expand, differentiate 
into PC and mediate disease via autoAb production and antigen presentation. CD19hi B 
cells, exhibiting a recently activated memory phenotype, were associated with other 
immune cells (Foxp3lo T cells) and clinical abnormalities (lower C3/C4) related to SLE.  
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Our most significant finding was the identification of urine immune cells, specifically B 
cells that very likely reside in the kidney. Further analyses showed significant 
correlations between urine PBs/PCs, high levels of urine IFNα and CKD/ESRD. Our 
data provide evidence that the use of SLE urine is practical and beneficial in the 
understanding of LN.  Once the identity of autoreactive B cells is established, the 
underlying pathogenic mechanisms can be determined and innovative approaches that 
specifically target them can be developed. 
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